CN115902217B - Indirect ELISA (enzyme-Linked immuno sorbent assay) detection kit for bovine paratuberculosis and application thereof - Google Patents
Indirect ELISA (enzyme-Linked immuno sorbent assay) detection kit for bovine paratuberculosis and application thereof Download PDFInfo
- Publication number
- CN115902217B CN115902217B CN202310215284.5A CN202310215284A CN115902217B CN 115902217 B CN115902217 B CN 115902217B CN 202310215284 A CN202310215284 A CN 202310215284A CN 115902217 B CN115902217 B CN 115902217B
- Authority
- CN
- China
- Prior art keywords
- serum
- paratuberculosis
- bovine
- indirect elisa
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002965 ELISA Methods 0.000 title claims abstract description 126
- 238000001514 detection method Methods 0.000 title claims abstract description 84
- 241000283690 Bos taurus Species 0.000 title claims abstract description 49
- 208000026681 Paratuberculosis Diseases 0.000 title claims abstract description 38
- 210000002966 serum Anatomy 0.000 claims abstract description 151
- 239000011248 coating agent Substances 0.000 claims abstract description 78
- 238000000576 coating method Methods 0.000 claims abstract description 78
- 238000000034 method Methods 0.000 claims abstract description 71
- 239000000243 solution Substances 0.000 claims description 87
- 241000187482 Mycobacterium avium subsp. paratuberculosis Species 0.000 claims description 67
- 230000000903 blocking effect Effects 0.000 claims description 47
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 34
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 29
- 230000001580 bacterial effect Effects 0.000 claims description 27
- 239000000872 buffer Substances 0.000 claims description 27
- 239000007788 liquid Substances 0.000 claims description 25
- 238000005406 washing Methods 0.000 claims description 21
- 239000001963 growth medium Substances 0.000 claims description 17
- 239000002609 medium Substances 0.000 claims description 17
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical group [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 claims description 16
- 235000020183 skimmed milk Nutrition 0.000 claims description 16
- 239000012089 stop solution Substances 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 15
- 241000187481 Mycobacterium phlei Species 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 9
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 9
- 235000009582 asparagine Nutrition 0.000 claims description 9
- 229960001230 asparagine Drugs 0.000 claims description 9
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 8
- 238000005119 centrifugation Methods 0.000 claims description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims description 8
- 238000001179 sorption measurement Methods 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 6
- 239000008121 dextrose Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 102000016938 Catalase Human genes 0.000 claims description 4
- 108010053835 Catalase Proteins 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000011148 porous material Substances 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 2
- 238000013016 damping Methods 0.000 claims 1
- 229940055036 mycobacterium phlei Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 abstract description 84
- 102000036639 antigens Human genes 0.000 abstract description 84
- 108091007433 antigens Proteins 0.000 abstract description 84
- 238000011161 development Methods 0.000 abstract description 28
- 230000035945 sensitivity Effects 0.000 abstract description 17
- 241001465754 Metazoa Species 0.000 abstract description 12
- 244000005700 microbiome Species 0.000 abstract 1
- 239000000306 component Substances 0.000 description 70
- 238000012360 testing method Methods 0.000 description 38
- 238000002474 experimental method Methods 0.000 description 36
- 238000010790 dilution Methods 0.000 description 30
- 239000012895 dilution Substances 0.000 description 30
- 235000018102 proteins Nutrition 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 27
- 238000005457 optimization Methods 0.000 description 26
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 22
- 238000012216 screening Methods 0.000 description 19
- 239000002953 phosphate buffered saline Substances 0.000 description 18
- 241000894006 Bacteria Species 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000011534 incubation Methods 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 230000009471 action Effects 0.000 description 10
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000000502 dialysis Methods 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 239000000654 additive Substances 0.000 description 8
- 244000061456 Solanum tuberosum Species 0.000 description 7
- 235000002595 Solanum tuberosum Nutrition 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 210000002421 cell wall Anatomy 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 238000007865 diluting Methods 0.000 description 6
- 238000001641 gel filtration chromatography Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000037029 cross reaction Effects 0.000 description 5
- 238000000432 density-gradient centrifugation Methods 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 201000008827 tuberculosis Diseases 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 238000012136 culture method Methods 0.000 description 4
- 244000144980 herd Species 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000012510 hollow fiber Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000012562 protein A resin Substances 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 238000002525 ultrasonication Methods 0.000 description 3
- 241000271566 Aves Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- MUUGCDGGIVCSDT-UHFFFAOYSA-N [NH4+].[NH4+].[O-]S([O-])(=O)=O.CCCCCCCC(O)=O Chemical compound [NH4+].[NH4+].[O-]S([O-])(=O)=O.CCCCCCCC(O)=O MUUGCDGGIVCSDT-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 235000014705 isoleucine Nutrition 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 235000008729 phenylalanine Nutrition 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000712005 Bovine respirovirus 3 Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- GCSNAXXOAPCMDD-UHFFFAOYSA-N CC=1C=C(C=C(C1N)C)C1=CC(=C(N)C(=C1)C)C.CN(C1=CC=C(C2=CC=C(N(C)C)C=C2)C=C1)C Chemical compound CC=1C=C(C=C(C1N)C)C1=CC(=C(N)C(=C1)C)C.CN(C1=CC=C(C2=CC=C(N(C)C)C=C2)C=C1)C GCSNAXXOAPCMDD-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000010711 Cattle disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000202957 Mycoplasma agalactiae Species 0.000 description 1
- 241001138504 Mycoplasma bovis Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 101100012902 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FIG2 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000036695 Syndromic diarrhea Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010051511 Viral diarrhoea Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- FRHBOQMZUOWXQL-UHFFFAOYSA-L ammonium ferric citrate Chemical compound [NH4+].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FRHBOQMZUOWXQL-UHFFFAOYSA-L 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000021735 chronic enteritis Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003050 experimental design method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000004313 iron ammonium citrate Substances 0.000 description 1
- 235000000011 iron ammonium citrate Nutrition 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- FEWLMSPFBRVAOJ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1.FS(=O)(=O)CC1=CC=CC=C1 FEWLMSPFBRVAOJ-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 238000012106 screening analysis Methods 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 208000007004 trichohepatoenteric syndrome Diseases 0.000 description 1
- 235000014393 valine Nutrition 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
技术领域Technical Field
本发明涉及一种牛副结核病间接ELISA检测试剂盒及其应用。本发明属于微生物检测技术领域。The invention relates to an indirect ELISA detection kit for bovine paratuberculosis and its application, and belongs to the technical field of microbial detection.
背景技术Background Art
禽分枝杆菌副结核亚种(Mycobacterium aviumsubsp.paratuberculosis,MAP)是副结核病(Paratuberculosis,PTB)或约内氏病(Johne’s disease,JD)的病原菌,PTB是一种进行性、感染性、肉芽肿性的慢性肠炎,宿主范围主要为反刍动物,特别是奶牛和各种驯养动物。上世纪初,由于交通工具的发达使得动物可以在世界各地移动,导致PTB在全球开始流行,在大多数重要的乳制品生产国,奶牛中MAP感染的群体流行率超过50%,感染副结核的病牛不适用于育种,同时病牛的出售极易感染其他牛群,造成不可挽回的损失,对全球的经济产生了严重的影响。PTB的这种长距离、渐进性、不易让人察觉的传播主要是由于存在大量的潜伏感染病例,且MAP这种病原菌对不利环境因素具有高度抵抗力,这些因素都构成了MAP传播的风险。同时,PTB是一种易感宿主范围很广(包括非人灵长类动物)的疾病。 Mycobacterium avium subsp. paratuberculosis (MAP) is the causative agent of paratuberculosis (PTB) or Johne's disease (JD), a progressive, infectious, granulomatous, chronic enteritis that primarily affects ruminants, especially dairy cows and various domesticated animals. In the early 20th century, the development of transportation allowed animals to move around the world, leading to a global prevalence of PTB. In most major dairy producing countries, the herd prevalence of MAP infection in dairy cows exceeded 50%. Paratuberculosis-infected cows are unsuitable for breeding, and the sale of sick cows can easily infect other herds, causing irreparable losses and having a serious impact on the global economy. This long-distance, gradual, and unnoticeable spread of PTB is mainly due to the presence of a large number of latent infection cases and the high resistance of the pathogen to adverse environmental factors, all of which constitute the risk of MAP transmission. At the same time, PTB is a disease with a wide range of susceptible hosts, including non-human primates.
近年来我国养牛业不断地扩大,但由于多数牛场管理不当,饲养密度过高,卫生环境差,导致PTB的传播越来越迅速,发病率显著上升,牛感染MAP后,由于MAP可以通过胎盘垂直传播,病牛不在适用于育种,牛奶产量降低,同时病牛的出售极易感染其他牛群,给畜牧业带来难以估量的损失。我国农业部规定,PTB为二类动物疫病,MAP属于三类动物病原微生物。In recent years, my country's cattle industry has been expanding. However, due to improper management of most cattle farms, high stocking density and poor sanitary environment, PTB has spread more and more rapidly, and the incidence rate has increased significantly. After cattle are infected with MAP, MAP can be transmitted vertically through the placenta, so sick cows are no longer suitable for breeding, and milk production is reduced. At the same time, the sale of sick cows is very likely to infect other herds, causing immeasurable losses to the animal husbandry industry. According to the Ministry of Agriculture of my country, PTB is a Class II animal epidemic disease and MAP is a Class III animal pathogenic microorganism.
目前,没有有效的预防该病的方法,病牛一般在疾病的后期才表现出临床症状,且药物无法治疗,同时由于其传播途径广泛,容易干扰结核病的检测,所以不宜采用主动免疫的方法。针对该病,在加强饲养管理,规范养殖方法的同时,唯一的办法就是定期检测,疑似动物隔离,患病动物淘汰。At present, there is no effective way to prevent the disease. Sick cattle generally show clinical symptoms in the late stage of the disease, and drugs cannot treat it. At the same time, due to its wide transmission routes, it is easy to interfere with the detection of tuberculosis, so active immunization is not suitable. In response to this disease, while strengthening feeding management and standardizing breeding methods, the only way is to conduct regular testing, isolate suspected animals, and eliminate sick animals.
在现有的诊断方法中,镜检具有灵敏度和特异性低的缺点,同时也会受到环境中的其他分枝杆菌的影响,使得检测结果为假阳性。由于亚临床阶段,患病动物排出体外的细菌含量少,使得细菌培养敏感性低,同时细菌培养为阴性的还需要重新检测,耗时长,成本高,限制了MAP的快速识别鉴定。免疫组化具有良好的敏感性但是可能存在交叉反应。Among the existing diagnostic methods, microscopic examination has the disadvantages of low sensitivity and specificity, and is also affected by other mycobacteria in the environment, resulting in false positive test results. Due to the subclinical stage, the amount of bacteria excreted from the body by sick animals is small, making bacterial culture sensitivity low. At the same time, negative bacterial cultures need to be retested, which is time-consuming and costly, limiting the rapid identification of MAP. Immunohistochemistry has good sensitivity but may have cross-reactions.
其中,关于MAP细胞免疫方面的检测已经进行了很多的研究,但是主要受限于3个原因:(1)在所有感染MAP的动物中没有发现特异性抗原能够普遍刺激细胞因子或是细胞的其他指示剂;(2)动物感染MAP后是否具有强烈的细胞免疫应答尚未清楚;(3)这种检测成本很高。同时,诊断成本的控制也是检测和预防PTB的重要因素,检测的花费不能超过疾病本身所造成的损失。所以,ELISA以操作简便、灵敏度高、特异性好,适用于大规模筛选定性的特点,非常适用于牛场PTB的检测。但是由于在检测过程中,结核病会干扰PTB的检测,目前国内没有很有效的抗原,既能检测出PTB又不受到结核病的干扰。Among them, a lot of research has been done on the detection of MAP cellular immunity, but it is mainly limited by three reasons: (1) No specific antigens have been found in all animals infected with MAP that can universally stimulate cytokines or other indicators of cells; (2) It is not clear whether animals have a strong cellular immune response after being infected with MAP; (3) The cost of this test is very high. At the same time, the control of diagnostic costs is also an important factor in the detection and prevention of PTB. The cost of the test cannot exceed the loss caused by the disease itself. Therefore, ELISA is easy to operate, highly sensitive, and specific, and is suitable for large-scale screening and qualitative analysis. It is very suitable for the detection of PTB in cattle farms. However, since tuberculosis can interfere with the detection of PTB during the detection process, there is currently no very effective antigen in China that can detect PTB without being interfered with by tuberculosis.
因此,目前迫切需要找到具有良好抗原性的包被原,同时应用该抗原建立一种牛副结核病间接ELISA检测的方法。Therefore, it is urgent to find a coating source with good antigenicity and establish an indirect ELISA detection method for bovine paratuberculosis using the antigen.
发明内容Summary of the invention
本发明的目的在于提供一种牛副结核病间接ELISA检测试剂盒及其应用。The invention aims to provide an indirect ELISA detection kit for bovine paratuberculosis and application thereof.
为了达到上述目的,本发明采用了以下技术手段:In order to achieve the above object, the present invention adopts the following technical means:
本发明通过优化MAP培养基组分和培养条件,分析MAP的各种亚细胞组分的生物学特性,成功筛选出了具有良好反应原性的亚细胞组分,接着对亚细胞组分采用组分分离、非特异性蛋白吸附处理等方法,获得效果最佳的包被抗原,应用该亚细胞组分作为包被抗原,进行牛副结核病间接ELISA抗体检测方法条件的优化、阴阳性临界值的确定及效果评价。结果表明:建立的间接ELISA方法敏感性为92.0%,特异性为95.5%,批内和批间的变异系数均小于10%,组装成试剂盒后,可稳定保存12个月。对来自于不同省市的1900份临床血清样本进行检测,PTB的阳性率为5.05%。The present invention optimizes the MAP culture medium components and culture conditions, analyzes the biological characteristics of various subcellular components of MAP, successfully screens out subcellular components with good reactivity, and then uses component separation, non-specific protein adsorption treatment and other methods to obtain the best coating antigen. The subcellular component is used as the coating antigen to optimize the conditions of the indirect ELISA antibody detection method for bovine paratuberculosis, determine the positive and negative critical values, and evaluate the effect. The results show that the established indirect ELISA method has a sensitivity of 92.0%, a specificity of 95.5%, and a coefficient of variation within and between batches of less than 10%. After being assembled into a kit, it can be stably stored for 12 months. 1900 clinical serum samples from different provinces and cities were tested, and the positive rate of PTB was 5.05%.
在上述研究的基础上,本发明提出了一种牛副结核病间接ELISA检测试剂盒,所述的试剂盒中包括禽分枝杆菌副结核亚种的培养滤液包被的酶标板,其中所述的禽分枝杆菌副结核亚种的培养滤液是通过以下方法制备得到的:Based on the above research, the present invention proposes an indirect ELISA detection kit for bovine paratuberculosis, wherein the kit comprises an ELISA plate coated with a culture filtrate of avian Mycobacterium paratuberculosis subspecies, wherein the culture filtrate of avian Mycobacterium paratuberculosis subspecies is prepared by the following method:
(1)将包含109 CFU /mL的禽分枝杆菌副结核亚种接种至含有0.05% v/v Tween-80、0.2% v/v甘油、5 mM天冬酰胺以及10% v/v的自制ADC的7H9培养基中,37℃恒温160 rpm培养10周,收集菌液;其中,所述的自制ADC是通过以下方法制备得到:NaCl 8.5 g,右旋-Dextrose 20.0 g,过氧化氢酶 0.03 g,定容到1 L,0.22 µm滤器过滤除菌;(1) Inoculate 10 9 CFU/mL of Mycobacterium paratuberculosis subspecies into 7H9 medium containing 0.05% v/v Tween-80, 0.2% v/v glycerol, 5 mM asparagine and 10% v/v homemade ADC, culture at 37°C and 160 rpm for 10 weeks, and collect the bacterial liquid; wherein the homemade ADC is prepared by the following method: NaCl 8.5 g, Dextrose 20.0 g, catalase 0.03 g, dilute to 1 L, and filter and sterilize with a 0.22 µm filter;
(2)将收集到的菌液进行离心,上清用0.22 μm孔径的滤膜过滤后为培养滤液。(2) The collected bacterial liquid is centrifuged and the supernatant is filtered through a 0.22 μm pore size filter membrane to obtain the culture filtrate.
其中,优选的,培养滤液包被酶标板的浓度为50 μg/mL。Preferably, the concentration of the culture filtrate coated on the ELISA plate is 50 μg/mL.
其中,优选的,步骤(2)中所述的离心是指10000 rpm 4℃ 离心30 min。Preferably, the centrifugation in step (2) refers to centrifugation at 10,000 rpm and 4°C for 30 min.
其中,优选的,所述的试剂盒中还包括包被缓冲液、封闭液、浓缩洗涤液、HRP标记后的兔抗牛IgG抗体、显色液以及终止液。Preferably, the kit further comprises a coating buffer, a blocking solution, a concentrated washing solution, an HRP-labeled rabbit anti-bovine IgG antibody, a color developing solution and a stop solution.
其中,优选的,所述的包被缓冲液为20 mmol/L Tris-HCl缓冲液,所述的封闭液为1% v/v脱脂乳+5% v/v猪血清,所述的浓缩洗涤液为PBST,所述的显色液为TMB显色液,所述的终止液为0.05% v/v的氢氟酸。Among them, preferably, the coating buffer is 20 mmol/L Tris-HCl buffer, the blocking solution is 1% v/v skim milk + 5% v/v pig serum, the concentrated washing solution is PBST, the color developing solution is TMB color developing solution, and the stop solution is 0.05% v/v hydrofluoric acid.
进一步的,本发明还提出了所述的牛副结核病间接ELISA检测试剂盒在制备检测或者诊断牛副结核病的试剂中的用途。Furthermore, the present invention also proposes the use of the bovine paratuberculosis indirect ELISA detection kit in preparing a reagent for detecting or diagnosing bovine paratuberculosis.
其中,优选的,所述的试剂为间接ELISA检测试剂。Among them, preferably, the reagent is an indirect ELISA detection reagent.
相较于现有技术,本发明的有益效果是:Compared with the prior art, the present invention has the following beneficial effects:
本发明成功筛选出具有良好抗原性的包被原,同时应用该抗原建立了牛副结核病间接ELISA检测试剂盒及其检测方法。实验过程中,全程采用副结核阳性血清、结核阳性血清和阴性血清3种血清进行检测,以建立能够消除结核病对PTB检测影响间接ELISA的方法。实验中,在确立各个步骤的最佳条件时,采用广泛筛选和重点重复相结合的方法,尽可能筛选出最优条件,部分条件筛选时,选择正交试验设计的方法,不仅减少了操作步骤,更提高了结果的准确性。通过对100份MAP阳性血清的检测,得出本方法敏感性为93.0%。通过对200份MAP阴性血清的检测得出本方法特异性为95.5%。明显高于其他检测方法。The present invention successfully screens out a coating source with good antigenicity, and at the same time uses the antigen to establish an indirect ELISA detection kit for bovine paratuberculosis and a detection method thereof. During the experiment, three types of sera, paratuberculosis positive serum, tuberculosis positive serum and negative serum, were used for detection throughout the process to establish an indirect ELISA method that can eliminate the influence of tuberculosis on PTB detection. In the experiment, when establishing the optimal conditions for each step, a method combining extensive screening and focused repetition was adopted to screen out the optimal conditions as much as possible. When screening some conditions, an orthogonal experimental design method was selected, which not only reduced the operating steps, but also improved the accuracy of the results. Through the detection of 100 MAP positive sera, it was concluded that the sensitivity of this method was 93.0%. Through the detection of 200 MAP negative sera, it was concluded that the specificity of this method was 95.5%. It is significantly higher than other detection methods.
本实验建立的牛副结核病间接ELISA检测的方法具有快速准确,敏感性和特异性高的特点。为预防和清除该病,保护我国畜牧业健康快速的发展提供技术支撑。The indirect ELISA method for bovine paratuberculosis established in this experiment is rapid, accurate, sensitive and specific, providing technical support for preventing and eliminating the disease and protecting the healthy and rapid development of my country's animal husbandry.
附图说明BRIEF DESCRIPTION OF THE DRAWINGS
图1为包被抗原初步筛选结果;Figure 1 shows the preliminary screening results of coating antigens;
图2为包被抗原培养过程的初步优化结果;FIG2 is a preliminary optimization result of the coated antigen culture process;
图3为 CF凝胶过滤层析纯化结果;Fig. 3 is the purification result of CF gel filtration chromatography;
图4为蔗糖密度梯度离心后收集组分示意图;Fig. 4 is a schematic diagram of fraction collection after sucrose density gradient centrifugation;
图5为M.Phlei和Msg制备的兔血清效价检测;Figure 5 shows the titer test of rabbit serum prepared by M.Phlei and Msg;
图6为抗原包被浓度的初步优化;Figure 6 shows the preliminary optimization of antigen coating concentration;
图7为封闭液的初步筛选;Figure 7 shows the preliminary screening of blocking solutions;
图8为各因素对A/N值的影响;Figure 8 shows the influence of various factors on the A/N value;
图9为五种二抗不同稀释倍数A/N值;Figure 9 shows the A/N values of five secondary antibodies at different dilution factors;
图10为五种二抗不同稀释倍数A/B值;Figure 10 shows the A/B values of five secondary antibodies at different dilution factors;
图11为血清样本及二抗作用时间的优化;Figure 11 shows the optimization of serum samples and secondary antibody action time;
图12为显色液和终止液的筛选;FIG12 is a screen of a color developing solution and a stop solution;
图13为阴性血清OD630nm值的直方图和正态分布图;Figure 13 is a histogram and normal distribution diagram of negative serum OD630nm values;
图14为特异性检测。Figure 14 shows specificity detection.
符号说明:Explanation of symbols:
具体实施方式DETAILED DESCRIPTION
下面结合具体实施例对本发明作进一步说明,但本发明不限于以下实施例。本领域技术人员应该理解的是,在不偏离本发明的精神及范围下可对本发明技术方案的细节和形式进行修改或替换,但这些修改和替换均落入本发明的保护范围内。The present invention is further described below in conjunction with specific embodiments, but the present invention is not limited to the following embodiments. It should be understood by those skilled in the art that the details and forms of the technical solution of the present invention can be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the protection scope of the present invention.
实施例1抗原的筛选及优化Example 1 Screening and optimization of antigens
1 材料和试剂1 Materials and reagents
1.1材料1.1 Materials
实验用菌种:研发本试剂盒抗原用菌种为MAP P18菌株,购自中国生物制品鉴定所,由哈尔滨兽医研究所保管和应用。4~8月龄健康犊牛2头,由中国农业科学院哈尔滨兽医研究所实验动物中心提供。Experimental strains: The strain used for the antigen development of this kit is MAP P18, purchased from the China Institute for the Identification of Biological Products, and kept and used by the Harbin Veterinary Research Institute. Two healthy calves aged 4 to 8 months were provided by the Experimental Animal Center of the Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences.
1.2试剂1.2 Reagents
酶标板购自costar公司;TMB显色液购自天根公司;7H9培养基购自BD公司;PROCLIN -300防腐剂和弗氏不完全佐剂购自sigma公司、Protein A树脂购自GE公司;BCA蛋白定量检测试剂盒购自Abcam。ELISA plates were purchased from Costar; TMB colorimetric solution was purchased from Tiangen; 7H9 culture medium was purchased from BD; PROCLIN-300 preservative and Freund's incomplete adjuvant were purchased from Sigma, Protein A resin was purchased from GE; BCA protein quantitative detection kit was purchased from Abcam.
1.3仪器1.3 Instruments
酶标仪-ELX800购自美国BioTeK公司;AKTA蛋白纯化系统购自GE公司。The ELX800 microplate reader was purchased from BioTeK, USA; the AKTA protein purification system was purchased from GE.
2 方法2 Methods
2.1试验用血清来源及制备2.1 Source and preparation of serum for the experiment
(1)阴性血清来源及制备(1) Source and preparation of negative serum
挑选4~8月龄健康未免疫犊牛1头,经检测MAP和MTB抗体均为阴性(副结核分枝杆菌抗体检测试剂盒及牛分枝杆菌抗体检测试剂盒检测抗体均为阴性,均购自美国IDEXX公司)。颈静脉采血,37℃ 静置2小时后分离血清(淡黄色澄清液体),将分离的血清经56℃ 水浴灭活30分钟后,按血清量的0.04%加入PROCLIN -300防腐剂,经0.22 µm滤器过滤除菌,无菌定量分装,3mL/瓶,2~8℃ 保存。A healthy non-immunized calf aged 4 to 8 months was selected, and the MAP and MTB antibodies were negative (both the Mycobacterium paratuberculosis antibody detection kit and the Mycobacterium bovis antibody detection kit were negative, both purchased from IDEXX, USA). Blood was collected from the jugular vein, and the serum (light yellow clear liquid) was separated after standing at 37°C for 2 hours. The separated serum was inactivated in a 56°C water bath for 30 minutes, and PROCLIN-300 preservative was added at 0.04% of the serum volume, filtered and sterilized with a 0.22 µm filter, and aseptically quantitatively packaged in 3 mL/bottle and stored at 2-8°C.
(2)MAP阳性血清来源及制备(2) Source and preparation of MAP-positive serum
来自于已知感染畜群,临床观察及剖检结果均证明感染了MAP的病牛,且肠内容物培养为阳性,同时使用IDEXX公司的副结核分枝杆菌抗体检测试剂盒检测,结果显示为MAP强阳性,将该牛颈静脉采血,分离血清方法同阴性血清。The sick cows came from known infected herds. Clinical observations and autopsy results proved that they were infected with MAP, and the intestinal contents were cultured positive. At the same time, the Mycobacterium paratuberculosis antibody detection kit from IDEXX was used for testing, and the results showed a strong positive for MAP. Blood was collected from the jugular vein of the cow, and the serum was separated using the same method as the negative serum.
(3)MTB阳性血清来源及制备(3) Source and preparation of MTB positive serum
挑选4~8月龄健康未免疫犊牛1头,免疫7083E6蛋白(由中国农业科学院哈尔滨兽医研究所细菌病实验室提供的结核分枝杆菌特异性蛋白),二免2周后颈静脉采血,分离血清。A healthy non-immunized calf aged 4 to 8 months was selected and immunized with 7083E6 protein (a Mycobacterium tuberculosis-specific protein provided by the Bacterial Disease Laboratory of Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences). Blood was collected from the
2.2 MAP菌落的培养2.2 Cultivation of MAP colonies
2.2.1W-R氏土豆培养基的制备2.2.1 Preparation of W-R potato culture medium
(1)液体W-R氏培养基的制备(1L)(1) Preparation of liquid W-R medium (1 L)
取蒸馏水950 mL(除去甘油的体积)分成两部分,分别放入100℃水浴,向其中一部分加入天冬酰胺,令其溶解。再用100 mL烧杯(瓶)取另一部分水浴后的蒸馏水按上述顺序分别溶解上述试剂,并按以上顺序将溶解的试剂加到天冬酰胺溶液中,然后加入甘油48mL,A液和B液各1.33 mL,用1 M NaOH调pH至7.2,过滤。Take 950 mL of distilled water (excluding the volume of glycerol) and divide it into two parts. Put them into a 100℃ water bath respectively. Add asparagine to one part and dissolve it. Then use a 100 mL beaker (bottle) to take another part of the distilled water after the water bath to dissolve the above reagents in the above order, and add the dissolved reagents to the asparagine solution in the above order. Then add 48 mL of glycerol, 1.33 mL of solution A and solution B respectively, adjust the pH to 7.2 with 1 M NaOH, and filter.
A液:Liquid A:
B液:Liquid B:
5% CaCl2溶液5% CaCl 2 solution
(2)鲜土豆块的制作(2) Preparation of fresh potato cubes
取鲜土豆中间圆形柱状部分,沿对角线分割成两部分,在清水流水中浸泡24 h。Take the round columnar part in the middle of a fresh potato, cut it into two parts along the diagonal line, and soak them in clean running water for 24 hours.
(3)培养基高压(3) High pressure culture medium
取一部分W-R液体培养基,将土豆浸泡其中,70℃ 水浴2 h,冷却半小时后。剩余的W-R液体培养基倒入试管中,每管约40 mL,将水浴处理后的土豆块放于试管上部卡住,盖塞封严,121℃高压灭菌15-20 min。Take a portion of W-R liquid medium, soak the potatoes in it, place in a 70℃ water bath for 2 hours, and cool for half an hour. Pour the remaining W-R liquid medium into test tubes, about 40 mL per tube, place the potato pieces treated in the water bath on the top of the test tube, seal the cap tightly, and sterilize at 121℃ for 15-20 minutes.
2.2.2MAP W-R氏土豆培养基的培养2.2.2 Cultivation of MAP W-R potato medium
将MAP P18菌株接种在W-R土豆培养基斜面上,37℃恒温培养4-6周后,生长出细小,直径约1mm、眼观微白色、表面隆起呈圆形,边缘略薄的不规则的菌落,该菌落即为MAP。The MAP P18 strain was inoculated on a slope of a W-R potato culture medium and cultured at 37°C for 4-6 weeks. Small, slightly white, irregular colonies with a diameter of about 1 mm and a rounded surface and slightly thin edges grew out. These colonies were MAP.
2.3 抗原的筛选2.3 Antigen screening
2.3.1MAP的培养2.3.1 Cultivation of MAP
将100μL(下文如不特殊提到,接入的菌种皆为干菌进行保留活性的破碎处理后的菌液)包含109CFU/mL的菌种接种至7H9培养基中,由于培养基中未添加抗性,所以每种做三个重复防止污染,37℃恒温 160 rpm培养8周后,收集菌液。100 μL (all inoculated bacteria are broken dry bacteria that retain activity, unless otherwise specified) containing 10 9 CFU/mL of bacteria was inoculated into 7H9 medium. Since no resistance was added to the medium, three replicates were made for each type to prevent contamination. After culturing at 37°C and 160 rpm for 8 weeks, the bacterial solution was collected.
2.3.2细菌亚细胞组分分离2.3.2 Separation of bacterial subcellular components
将收集到的菌液进行亚细胞组分分离,取50 mL MAP培养物10,000 rpm 4℃ 离心30 min,上清用0.22 μm孔径的滤膜过滤后为培养滤液(culture filtrate,CF),将一部分CF进行煮沸灭活处理。菌体用1×PBS洗涤后,分别用包含PMSF(终浓度1 mM)和不包含PMSF的PBS重悬,冰浴超声15 min(超声5s,停5s),冰上静置15 min后再超声15 min。超声产物于3000 g 4℃ 离心5 min后再于100,000 g 4℃ 离心4h,上清转移备用。此时上清即为胞浆成分,沉淀为胞壁和胞膜的混合成分。另取10mL MAP培养物,进行微超声处理后分离CF和菌体,用1mL 20mM Tris-HCl(pH=8.0)重悬菌体,加入终浓度0.05% Tween-80,振幅5% 超声30s(超声3s,停止3s)后10000 rpm 4℃离心2 min,收集上清,此为细胞壁成分,与CF混合后,形成胞壁和CF混合组分,使用BCA蛋白定量检测试剂盒测定CF(组分1)、灭活后CF(组分2)、胞浆(组分3)、未经PMSF处理的胞浆(组分4)、胞膜和胞壁混合组分(组分5)、未经PMSF处理的胞膜和胞壁混合组分(组分6)和胞壁和CF混合组分(组分7)的浓度。The collected bacterial liquid was separated into subcellular components. 50 mL of MAP culture was centrifuged at 10,000 rpm and 4℃ for 30 min. The supernatant was filtered through a 0.22 μm pore size filter membrane to obtain the culture filtrate (CF). A portion of the CF was inactivated by boiling. The bacteria were washed with 1×PBS, resuspended with PBS containing PMSF (
2.3.3包被抗原的初步筛选2.3.3 Preliminary screening of coating antigens
采用间接ELISA方法进行检测,以CBS作为包被缓冲液,以组分1、组分2、组分3、组分4、组分5、组分6、组分7、全菌体(组分8)作为包被原,包被原包被浓度初设为50μg/mL,初步以5% 脱脂乳作为封闭液,以阴性血清(N)、MAP阳性血清(A)、MTB阳性血清(B)100倍稀释作为一抗,兔抗牛二抗(HRP标记)5,000倍稀释作为二抗,以TMB作为显色液(具体实施方式中所有显色液均为天根公司TMB显色液),以2M 硫酸作为终止液,整个操作过程稀释液和洗涤液均为PBST,每次洗涤3次,间隔3min,每孔均设两个平行对照,显色终止后读取OD450nm值。根据A/B和A/N值的大小判定抗原性的强弱。该部分实验进行三次重复,最终筛选出最优势的抗原。The indirect ELISA method was used for detection, with CBS as the coating buffer,
2.3.4包被抗原的优化2.3.4 Optimization of coating antigen
2.3.4.1包被抗原培养过程优化2.3.4.1 Optimization of the coating antigen culture process
将100μL包含109CFU /mL的菌种分别接种至100mL的7H9培养基(培养基1)、7H9+ADC培养基(培养基2)、7H9+自制ADC培养基(培养基3)、牛肉膏培养基(培养基4)中,37℃恒温 160 rpm分别培养4周、6周、8周、10周、12周后,收集菌液,通过亚细胞组分分离获得优势抗原组分,将不同处理组得到的优势抗原组分分别包被酶标板,进行间接ELISA检测,根据A/N和A/B值的大小判定不同培养组优势抗原组分抗原性的强弱,筛选出培养抗原的方式,所述的自制ADC是通过以下方法制备得到:NaCl 8.5g,右旋-Dextrose 20.0g,过氧化氢酶0.03g,定容到1L,0.22µm滤器过滤除菌。对该培养方式的抗原进一步优化,对该培养条件下的培养基做如下处理组,原成分组(组分1)、不添加甘油组(组分2)、添加双倍甘油含量组(组分3)、不添加Tween-80组(组分4)、添加双倍Tween-80含量组(组分5)、厌氧培养组(组分6),37℃ 恒温 160rpm培养,收集菌液,通过亚细胞组分分离获得优势抗原组分,将不同处理组得到的优势抗原组分分别包被酶标板,进行间接ELISA检测,根据A/B和A/N值的大小判定不同组分优势抗原抗原性的强弱,筛选出培养抗原的较优方式。再次对较优培养方式进行优化,将100μL包含109CFU /mL的菌种接种至上述较优的培养基中,向培养基中分别添加丝氨酸、赖氨酸、半胱氨酸、甘氨酸、缬氨酸、亮氨酸、谷氨酰胺、苯丙氨酸、谷氨酸、甲硫氨酸、天冬酰胺、丙氨酸、脯氨酸、苏氨酸、精氨酸、酪氨酸、组氨酸、异亮氨酸和抗坏血酸,添加物终浓度为5mM,同时设置无添加物的对照组,每组做两个重复,按上述较优培养方式培养后,收集菌液,通过亚细胞组分分离获得优势抗原组分,将添加不同成分处理组得到的优势抗原组分分别包被酶标板,进行间接ELISA检测,根据A/B和A/N值的大小判定不同添加物培养组的优势抗原组分抗原性的强弱,筛选出培养抗原的最佳添加成分。100 μL of the bacterial strain containing 10 9 CFU/mL was inoculated into 100 mL of 7H9 medium (medium 1), 7H9+ADC medium (medium 2), 7H9+self-made ADC medium (medium 3), and beef extract medium (medium 4), respectively. After culturing at 37°C and 160 rpm for 4 weeks, 6 weeks, 8 weeks, 10 weeks, and 12 weeks, the bacterial liquid was collected, and the dominant antigen components were obtained by subcellular component separation. The dominant antigen components obtained from different treatment groups were coated on enzyme-labeled plates, respectively, and indirect ELISA detection was performed. The antigenicity of the dominant antigen components in different culture groups was determined according to the size of A/N and A/B values, and the method of culturing antigens was screened. The self-made ADC was prepared by the following method: NaCl 8.5 g, Dextrose 20.0 g, catalase 0.03 g, fixed volume to 1 L, and filtered and sterilized with a 0.22 μm filter. The antigen of this culture method was further optimized, and the culture medium under this culture condition was treated with the following groups: original component group (component 1), group without glycerol addition (component 2), group with double glycerol content (component 3), group without Tween-80 addition (component 4), group with double Tween-80 content (component 5), and anaerobic culture group (component 6). The culture was carried out at a constant temperature of 37°C and 160rpm, and the bacterial liquid was collected. The dominant antigen components were obtained by subcellular component separation. The dominant antigen components obtained from different treatment groups were coated on ELISA plates, and indirect ELISA detection was performed. The strength of the antigenicity of the dominant antigens of different components was determined according to the size of the A/B and A/N values, and the better way to cultivate antigens was screened out. The optimal culture method was optimized again, 100 μL of bacteria containing 10 9 CFU / mL was inoculated into the above-mentioned optimal culture medium, and serine, lysine, cysteine, glycine, valine, leucine, glutamine, phenylalanine, glutamic acid, methionine, asparagine, alanine, proline, threonine, arginine, tyrosine, histidine, isoleucine and ascorbic acid were added to the culture medium respectively, with a final concentration of 5 mM. A control group without additives was set up at the same time, and two replicates were made for each group. After culturing according to the above-mentioned optimal culture method, the bacterial liquid was collected, and the dominant antigen components were obtained by subcellular component separation. The dominant antigen components obtained from the treatment groups with different components were coated on enzyme-labeled plates, and indirect ELISA detection was performed. The strength of the antigenicity of the dominant antigen components in the culture groups with different additives was determined according to the size of A/B and A/N values, and the optimal additive components for culturing antigens were screened out.
2.3.4.2包被抗原的单独优化2.3.4.2 Individual Optimization of Coating Antigen
为使包被抗原进一步优化,按上述优化条件分离包被抗原后,对包被抗原分别进行以下处理。In order to further optimize the coated antigen, after separating the coated antigen according to the above-mentioned optimized conditions, the coated antigen was subjected to the following treatments.
(1)凝胶过滤层析(1) Gel filtration chromatography
将所有的工作液(20% 乙醇,20 mM Tris-HCl(pH=8.0),去离子水)及包被抗原经过0.45 μm的滤膜过滤后,打开仪器,首先进行AKTA机器的清洗及管道准备,泵清洗结束后安装层析柱,将Superdex 200(分离范围20 kDa-200 kDa)的预装柱安装在AKTA上,检测波长为280 nm,预装柱经平衡后用样品环上样,开始运行程序,程序运行结束后,收集样品。收集每个峰下的样品以50 μg/mL的浓度分别包被酶标板,同时设置未处理过的包被抗原作为对照组,进行间接ELISA检测,根据A/B和A/N值的大小判定不同峰下各蛋白抗原性的强弱。After filtering all working solutions (20% ethanol, 20 mM Tris-HCl (pH=8.0), deionized water) and coated antigens through a 0.45 μm filter membrane, turn on the instrument, first clean the AKTA machine and prepare the pipeline. After the pump is cleaned, install the chromatography column, install the pre-loaded column of Superdex 200 (separation range 20 kDa-200 kDa) on the AKTA, the detection wavelength is 280 nm, the pre-loaded column is balanced and loaded with a sample loop, start running the program, and collect samples after the program runs. Collect samples under each peak and coat the ELISA plate at a concentration of 50 μg/mL. At the same time, set the untreated coated antigen as the control group for indirect ELISA detection, and determine the strength of the antigenicity of each protein under different peaks according to the size of the A/B and A/N values.
(2)包被抗原中20 kDa以下蛋白截留(2) Retention of proteins below 20 kDa in the coated antigen
通过中空纤维超滤实验装置对包被抗原中20kDa以下的蛋白进行截留,留下小分子量的蛋白的混合组分,按照5 μg/mL、10 μg/mL、20 μg/mL、35 μg/mL、50 μg/mL、100 μg/mL、150 μg/mL的浓度梯度包被酶标板,同时设置未截留的包被抗原作为对照组,进行间接ELISA检测,根据A/B和A/N值的大小判定不同浓度下抗原性的强弱。The proteins below 20 kDa in the coated antigen were retained by a hollow fiber ultrafiltration experimental device, leaving a mixed component of small molecular weight proteins, and coated on an ELISA plate according to a concentration gradient of 5 μg/mL, 10 μg/mL, 20 μg/mL, 35 μg/mL, 50 μg/mL, 100 μg/mL, and 150 μg/mL. At the same time, the unretained coated antigen was set as a control group for indirect ELISA detection, and the strength of the antigenicity at different concentrations was determined according to the A/B and A/N values.
(3)包被抗原纯蛋白衍生物制备(3) Preparation of pure protein derivatives for coating antigens
取包被抗原10 mL,每毫升添加苯酚3.0 g,混匀后于4~8℃ 静置4个小时,保留上清(样品1)弃沉淀,去除不容性蛋白,向上清中加入终浓度为 2%~4% 的40% 三氯醋酸,混匀后静置4~6小时,弃上清液(样品2),获得沉淀物,用1% 三氯醋酸洗涤沉淀物三次后 3,000rpm 离心收集沉淀物(样品3)。用PB将沉淀物全部溶解,向其中加入等量的饱和硫酸铵溶液,4℃ 过夜(样品4),将液体离心后收集沉淀物,加PB溶解得到粗提取的纯蛋白衍生物(样品5),将粗提物在PBS(每毫升添加苯酚3.0 g)中透析两次,制得精制纯蛋白衍生物(样品6)。收集制备过程中每一步的样品包被酶标板,同时设置未处理过的包被抗原作为对照组,进行间接ELISA检测,根据A/B和A/N值的大小判定每一步处理后包被抗原的抗原性的强弱。Take 10 mL of the coated antigen, add 3.0 g of phenol per mL, mix well and let stand at 4-8°C for 4 hours, retain the supernatant (sample 1) and discard the precipitate, remove the insoluble protein, add 40% trichloroacetic acid with a final concentration of 2%~4% to the supernatant, mix well and let stand for 4-6 hours, discard the supernatant (sample 2), obtain the precipitate, wash the precipitate three times with 1% trichloroacetic acid and collect the precipitate by centrifugation at 3,000rpm (sample 3). Dissolve all the precipitate with PB, add an equal amount of saturated ammonium sulfate solution to it, and let it stand at 4°C overnight (sample 4), collect the precipitate after centrifugation of the liquid, dissolve it with PB to obtain a crude extracted pure protein derivative (sample 5), and dialyze the crude extract twice in PBS (3.0 g of phenol added per mL) to obtain a refined pure protein derivative (sample 6). The samples from each step of the preparation process were collected and coated on ELISA plates. Untreated coated antigens were set as a control group for indirect ELISA testing. The strength of the antigenicity of the coated antigen after each step of treatment was determined based on the A/B and A/N values.
(4)蔗糖密度梯度离心(4) Sucrose density gradient centrifugation
选择三个梯度(20%,40%,60%)的蔗糖溶液,依次用长针管加入到离心管中,最后在最上层缓慢加入包被抗原,120,000g离心2h后,轻轻取出离心管,能够发现在20%到40%、40%到60%之间皆有一条明亮的带,分别吸取如图4所示8个部分的溶液,分别在PBS缓冲液中4℃过夜透析除糖,将该8种溶液分别包被酶标板,同时设置未处理过的包被抗原作为对照组,进行间接ELISA检测,根据A/B和A/N值的大小判定每一步处理后包被抗原的抗原性的强弱。Select three gradients (20%, 40%, 60%) of sucrose solution, add them into the centrifuge tube in sequence with a long needle, and finally slowly add the coated antigen to the top layer. After centrifugation at 120,000g for 2 hours, gently take out the centrifuge tube. It can be found that there is a bright band between 20% and 40% and between 40% and 60%. Pipette the solutions of the eight parts shown in Figure 4 respectively, dialyze them in PBS buffer at 4°C overnight to remove sugar, and coat the eight solutions on ELISA plates respectively. At the same time, set the untreated coated antigen as the control group for indirect ELISA detection. The strength of the antigenicity of the coated antigen after each step of treatment is determined according to the A/B and A/N values.
(5)非特异性反应蛋白的吸附(5) Adsorption of non-specific reactive proteins
首先用M. Phlei和Msg制备兔高免血清First, rabbit high immune serum was prepared using M. Phlei and Msg
选用雄性新西兰白兔,每只3 kg左右,购回饲养一周适应环境后开始免疫,每种细菌免疫两只兔子。免疫前兔耳缘静脉采血,分离血清后作为阴性对照。用无菌的PBS将M.Phlei和Msg稀释为2 mg/mL,与弗氏不完全佐剂1:1混合(按体重0.5mg/kg计算)后对家兔进行免疫,每间隔两周免疫一次。三次免疫7-10天后,于耳缘静脉采血2mL分离血清,进行抗体效价检测,将待测血清做倍比稀释(1:100;1:200;1:400;1:800;1:1,600;1:3,200;1:6,400;1:12,800;1:25,600;1:51,200;1:102,400;1:204,800),反应孔的OD值与阴性对照的比值大于或等于2判为阳性,以最高稀释倍数的孔为阳性的稀释倍数作为免疫血清的效价。抗体效价达到本实验要求后,收集全部血清。Male New Zealand white rabbits, weighing about 3 kg each, were purchased and raised for one week to adapt to the environment before immunization. Two rabbits were immunized with each bacterium. Blood was collected from the ear vein of the rabbit before immunization, and the serum was separated as a negative control. M.Phlei and Msg were diluted to 2 mg/mL with sterile PBS, mixed with Freund's incomplete adjuvant in a ratio of 1:1 (calculated based on body weight 0.5 mg/kg), and then immunized with rabbits every two weeks. 7-10 days after the third immunization, 2 mL of blood was collected from the ear vein to separate the serum for antibody titer detection. The serum to be tested was diluted in multiples (1:100; 1:200; 1:400; 1:800; 1:1,600; 1:3,200; 1:6,400; 1:12,800; 1:25,600; 1:51,200; 1:102,400; 1:204,800). The ratio of the OD value of the reaction well to the negative control was greater than or equal to 2 and was judged as positive. The dilution multiple of the highest dilution multiple was used as the titer of the immune serum. After the antibody titer reached the requirements of this experiment, all serum was collected.
辛酸-硫酸铵法初步纯化兔血清抗体Preliminary purification of rabbit serum antibodies by caprylic acid-ammonium sulfate method
将收集到的兔血清于12,000 rpm离心5 min后取上清5mL,向其中加入20mL的醋酸缓冲液,混合均匀后放入搅拌器中,一边缓慢搅拌一边加入1,875μL的正辛酸,继续搅拌30min后,立即于4℃ 12,000 rpm 离心30 min,收集上清。向每毫升上清中加入0.227g 硫酸铵,继续搅拌30 min,静置5h后4℃ 12,000 rpm 离心30 min,弃上清,沉淀用2.5 mL的PBS重悬。将悬液放入透析卡中用PBS透析,4℃ 透析过夜换液3次,最后收集透析卡中的溶液为初步纯化的兔血清抗体。After the collected rabbit serum was centrifuged at 12,000 rpm for 5 min, 5 mL of supernatant was taken, 20 mL of acetate buffer was added, and the mixture was placed in a stirrer. While slowly stirring, 1,875 μL of octanoic acid was added. After continuing to stir for 30 min, the mixture was immediately centrifuged at 4°C 12,000 rpm for 30 min, and the supernatant was collected. 0.227 g of ammonium sulfate was added to each milliliter of supernatant, and the mixture was continued to stir for 30 min. After standing for 5 h, the mixture was centrifuged at 4°C 12,000 rpm for 30 min, the supernatant was discarded, and the precipitate was resuspended in 2.5 mL of PBS. The suspension was placed in a dialysis card and dialyzed with PBS. The dialyzation was performed overnight at 4°C and the solution was changed 3 times. Finally, the solution in the dialysis card was collected as the preliminarily purified rabbit serum antibody.
包被抗原中非特异性蛋白的吸附Non-specific protein adsorption in coated antigen
准备3管ProteinA树脂,用buffer A 将树脂平衡10个柱体积后,将初步纯化的M.Phlei和Msg兔血清抗体分为M.Phlei组(样品1)、Msg组(样品2)和M.Phlei+Msg(1:1等浓度混合)混合组(样品3),分别穿过树脂,直至饱和。向三个树脂中分别加入等量包被抗原,作用10 min后,收集穿过液,用buffer B 洗杂,收集洗杂液后,将穿过液缓慢加入到树脂中,作用10 min后,再次收集穿过液,用bufferB洗杂,该过程重复5次后,收集所有的样品1组穿过液(样品4)和洗杂液(样品5)、样品2组穿过液(样品6)和洗杂液(样品7)、样品3组穿过液(样品8)和洗杂液(样品9),将收集到的样品4-9分别包被酶标板,同时设置未处理过的包被抗原作为对照组,进行间接ELISA检测,根据A/B和A/N值的大小判定6种样品抗原性的强弱。Three tubes of Protein A resin were prepared. After equilibrating the resin with buffer A for 10 column volumes, the preliminarily purified M.Phlei and Msg rabbit serum antibodies were divided into M.Phlei group (sample 1), Msg group (sample 2) and M.Phlei+Msg (1:1 equal concentration mixture) mixed group (sample 3), and passed through the resin separately until saturation. An equal amount of coated antigen was added to the three resins respectively. After 10 min of action, the flow-through was collected and washed with buffer B. After collecting the wash solution, the flow-through was slowly added to the resin. After 10 min of action, the flow-through was collected again and washed with buffer B. After repeating this
3 结果3 Results
3.1抗原的筛选3.1 Antigen screening
3.1.1包被抗原的初步筛选3.1.1 Preliminary screening of coating antigens
采用间接ELISA方法进行检测,以CBS作为包被缓冲液,以组分1、组分2、组分3、组分4、组分5、组分6、组分7、全菌体(组分8)作为包被原,包被原包被浓度为50 μg/mL,以阴性血清(N)、MAP阳性血清(A)、MTB阳性血清(B)100倍稀释作为一抗,兔抗牛二抗(HRP标记)5,000倍稀释作为二抗,显色终止后测定OD450nm值。酶标仪读值后对A/B及A/N的值进行分析,结果显示(见图1),组分1中A/B值相对较高,A/N的值最高,所以组分1的效果最好,即CF为最优势的包被抗原。The indirect ELISA method was used for detection, with CBS as the coating buffer, and
3.1.2包被抗原制备过程的优化3.1.2 Optimization of the coating antigen preparation process
将100 μL包含109CFU /mL的菌种分别接种至100 mL的培养基1-4中,37℃ 恒温160 rpm分别培养4周、6周、8周、10周、12周后,收集菌液,通过亚细胞组分分离获得CF,将不同处理组得到的CF分别包被酶标板,进行间接ELISA检测,酶标仪读值后对A/B及A/N的值进行分析结果显示(见图2),在培养基3的条件下,培养10周时A/N值最优,A/B值较优,所以7H9+自制ADC培养基培养10周为较优培养条件。考虑到培养基中的添加组分(Tween-80,甘油)可能会影响分泌的CF的效果,在该培养条件下,对培养基的添加物做组分1-6的优化,培养10周后,分离不同组分的CF包被酶标板,进行间接ELISA检测,酶标仪读值后对A/B及A/N的值进行分析,分析结果显示(见表1),组分1-5结果相差并不大,但是在培养过程中,组分2会影响细菌的浊度,按照组分4培养,细菌比其他组更容易污染,同时考虑到在实验过程中尽量节省材料,所以选择原培养基组分。所以初步优化培养条件为7H9(0.05% v/v Tween-80,0.2% v/v 甘油)+自制ADC培养基37℃恒温 160 rpm培养10周。考虑到不同的氨基酸可能对细菌生长过程中的蛋白的种类及含量产生影响,对上一步的包被抗原的培养方式进行再次优化,向培养基中分别添加18种氨基酸和抗坏血酸,终浓度均为5 mM,同时设置无添加物的对照组,每组做两个重复,37℃恒温 160 rpm培养10周后,收集菌液。分离出CF后分别包被酶标板,进行间接ELISA检测,酶标仪读值后对A/B及A/N的值进行分析,结果表明(见表2),综合A/N值和A/B值考虑,能提高包被抗原检测的敏感性和特异性的为赖氨酸、半胱氨酸、苯丙氨酸、天冬酰胺、丙氨酸、组氨酸和异亮氨酸添加物组;会降低包被抗原的检测敏感性和特异性的为谷氨酸和酪氨酸添加物组。进行相同条件下的重复实验,结果表明(见表2)赖氨酸和天冬酰胺组的重复性较好,但是考虑到赖氨酸组A/B值较低,检测特异性降低,所以结论是添加天冬酰胺能有效提高CF的检测敏感性和特异性。100 μL of the bacterial strain containing 10 9 CFU /mL was inoculated into 100 mL of culture medium 1-4, and cultured at 37°C and 160 rpm for 4, 6, 8, 10 and 12 weeks, respectively. The bacterial liquid was collected and CF was obtained by subcellular component separation. The CF obtained from different treatment groups were coated on ELISA plates and tested by indirect ELISA. The A/B and A/N values were analyzed after the ELISA instrument read the values. The results showed (see Figure 2) that under the conditions of
所以最终优化培养条件为禽分枝杆菌副结核亚种的培养滤液是通过以下方法制备得到的:Therefore, the final optimized culture condition is that the culture filtrate of Mycobacterium avium subspecies paratuberculosis is prepared by the following method:
(1)将包含109CFU /mL的禽分枝杆菌副结核亚种接种至含有0.05% v/v Tween-80、0.2% v/v甘油、5 mM天冬酰胺以及10% v/v的自制ADC的7H9培养基中,37℃恒温 160rpm培养10周,收集菌液;其中,所述的自制ADC是通过以下方法制备得到:NaCl 8.5 g,右旋-Dextrose 20.0 g,过氧化氢酶 0.03 g,定容到1 L,0.22 µm滤器过滤除菌;(1)
(2)将收集到的菌液进行离心,上清用0.22μm孔径的滤膜过滤后为培养滤液(CF)。(2) The collected bacterial liquid is centrifuged and the supernatant is filtered through a 0.22 μm pore size filter membrane to obtain the culture filtrate (CF).
3.2包被抗原分离后的检测效果比较3.2 Comparison of detection effects after separation of coated antigens
3.2.1凝胶过滤层析3.2.1 Gel filtration chromatography
将过滤后的CF通过凝胶过滤层析柱Superdex 200,程序运行结束后,通过图3可以看出,在47 mL、67 mL和116 mL处有较明显的吸收峰,分布在D区、F区和J区,分别收集最高峰下各管样品(D8、D9、F4、F5、J5、J6)以50 μg/mL的浓度包被酶标板,同时用未进行凝胶过滤层析的CF作为对照,进行间接ELISA检测,酶标仪读值后对A/B及A/N的值进行分析,结果表明(见表3)6管样品的A/N和A/B结果均不如未进行凝胶过滤层析前的CF检测值。说明在CF进行凝胶过滤层析纯化的过程中没有分离出比未纯化前更有优势的包被抗原。The filtered CF was passed through the gel
3.2.2包被抗原中20 kDa以下蛋白截留3.2.2 Retention of proteins below 20 kDa in the coated antigen
通过中空纤维超滤实验装置对包被抗原中20 kDa以下的蛋白进行截留,留下小分子量的蛋白的混合组分,按照5 μg/mL-150 μg/mL的浓度设置7个梯度分别包被酶标板,同时设置未截留的包被抗原(50 μg/mL)作为对照组,进行间接ELISA检测,酶标仪读值后对A/B及A/N的值进行分析,酶标仪读值后对A/B及A/N的值进行分析,结果表明(见表4),对照组的A/N和A/B的值明显优于截留后的小分子量蛋白的混合组分各浓度梯度的值。表明截留后的小分子量蛋白中没有明显优于原CF的有效包被抗原成分。The proteins below 20 kDa in the coated antigen were retained by the hollow fiber ultrafiltration experimental device, leaving the mixed components of small molecular weight proteins. Seven gradients were set according to the concentration of 5 μg/mL-150 μg/mL to coat the ELISA plate respectively. At the same time, the unretained coated antigen (50 μg/mL) was set as the control group for indirect ELISA detection. The values of A/B and A/N were analyzed after the ELISA instrument read the values. The results showed (see Table 4) that the values of A/N and A/B of the control group were significantly better than the values of each concentration gradient of the mixed components of the small molecular weight proteins after the retention. This shows that there is no effective coated antigen component in the small molecular weight protein after the retention that is significantly better than the original CF.
3.2.3包被抗原纯蛋白衍生物的检测3.2.3 Detection of pure protein derivatives of coated antigens
将包被抗原纯蛋白衍生物制备过程中每一步收集到的样品(共6种)分别包被酶标板,同时设置未处理过的包被抗原作为对照组,进行间接ELISA检测,结果表明(表5),6个样品的A/N和A/B值综合判定结果均不如对照组的值,表明包被抗原的纯蛋白衍生物及纯蛋白衍生物制备过程中并没有产生比原CF更有效的能够作为包被抗原的成分。The samples collected at each step in the preparation process of the pure protein derivatives of the coated antigen (a total of 6 types) were coated on ELISA plates respectively, and the untreated coated antigen was set as the control group for indirect ELISA detection. The results showed (Table 5) that the comprehensive judgment results of the A/N and A/B values of the 6 samples were not as good as those of the control group, indicating that the pure protein derivatives of the coated antigen and the preparation process of the pure protein derivatives did not produce components that were more effective than the original CF and could serve as coating antigens.
3.2.4包被抗原的蔗糖密度梯度离心分离3.2.4 Sucrose density gradient centrifugation of coated antigen
选择20%,40%,60% 三个梯度的蔗糖溶液对CF进行密度梯度离心,分别吸取如图4所示8个部分的溶液,分别在PBS缓冲液中透析除糖,将该8种溶液分别包被酶标板,同时设置未处理过的包被抗原作为对照组,进行间接ELISA检测,酶标仪读值后对A/B及A/N的值进行分析,结果表明(见表6),蔗糖密度梯度离心并没有分离出比原有抗原更有效的抗原成分。Three gradients of sucrose solutions of 20%, 40%, and 60% were selected to perform density gradient centrifugation on CF. The solutions of the eight parts shown in Figure 4 were respectively aspirated and dialyzed in PBS buffer to remove sugar. The eight solutions were coated on ELISA plates respectively, and untreated coated antigens were set as the control group for indirect ELISA detection. After the ELISA instrument read the values, the A/B and A/N values were analyzed. The results showed (see Table 6) that sucrose density gradient centrifugation did not separate antigen components that were more effective than the original antigens.
3.3包被抗原的非特异性蛋白吸附处理3.3 Nonspecific protein adsorption treatment of coated antigens
3.3.1兔高免血清效价检测3.3.1 Rabbit high immune serum titer test
将收集到的M.Phlei和Msg制备的血清进行抗体效价检测,将待测血清做倍比稀释(第一孔做1:100稀释,之后依次倍比稀释至1:204,800),同时以免疫前血清作为阴性对照,以M.Phlei和Msg作为包被抗原,进行间接ELISA检测,酶标仪读值后对结果进行分析。结果表明(见图5),二者血清效价均能达到102,400,符合本实验的要求。The collected serum prepared from M.Phlei and Msg was tested for antibody titer, and the serum to be tested was diluted in multiples (1:100 dilution in the first well, and then diluted in multiples to 1:204,800), and the pre-immune serum was used as a negative control, and M.Phlei and Msg were used as coating antigens for indirect ELISA detection. The results were analyzed after the microplate reader read the values. The results showed (see Figure 5) that the titers of both sera could reach 102,400, which met the requirements of this experiment.
3.3.2包被抗原中非特异性蛋白的吸附3.3.2 Adsorption of nonspecific proteins in coated antigens
将制备的兔高免血清用辛酸-硫酸铵法进行抗体的初步纯化后,加入Protein A树脂至饱和,向树脂中加入CF,收集所有纯化过程中的样品,将样品4-9分别包被酶标板,同时设置未处理过的包被抗原作为对照组,进行间接ELISA检测,酶标仪读值后对A/B及A/N的值进行分析,结果表明(见表7),对照组的A/B和A/N的值明显优于样品4-9组的值。表明未经处理的CF抗原性更好。After the prepared rabbit high immune serum was initially purified by the caprylic acid-ammonium sulfate method, Protein A resin was added to saturation, CF was added to the resin, and all samples in the purification process were collected. Samples 4-9 were coated with ELISA plates respectively, and untreated coated antigens were set as the control group for indirect ELISA detection. The A/B and A/N values were analyzed after the ELISA instrument read the values. The results showed (see Table 7) that the A/B and A/N values of the control group were significantly better than those of sample groups 4-9, indicating that the untreated CF had better antigenicity.
实施例2牛副结核病间接ELISA检测方法的建立Example 2 Establishment of indirect ELISA detection method for bovine paratuberculosis
1 材料和试剂1 Materials and reagents
1.1材料1.1 Materials
特异性质控血清由哈尔滨兽医研究所保存。雄性新西兰白兔-3kg,SPF级,购自哈尔滨兽医研究所工程中心。Specific quality control serum was stored by Harbin Veterinary Research Institute. Male New Zealand white rabbits-3 kg, SPF grade, were purchased from the Engineering Center of Harbin Veterinary Research Institute.
1.2试剂1.2 Reagents
羊抗牛多克隆抗体(HRP标记)购自KPL公司;四种兔抗牛二抗均购自sigma公司;购自sigma、上海生工、amresco 、thermo和天根公司的5种不同品牌的TMB显色液。Sheep anti-bovine polyclonal antibody (HRP labeled) was purchased from KPL Company; four rabbit anti-bovine secondary antibodies were all purchased from Sigma Company; five different brands of TMB colorimetric solutions were purchased from Sigma, Shanghai Bioengineering, Amresco, Thermo and Tiangen Company.
1.3仪器1.3 Instruments
酶标仪-ELX800购自美国BioTeK公司;中空纤维超滤实验装置购自北京旭邦膜设备有限责任公司。The ELX800 microplate reader was purchased from BioTeK, USA; the hollow fiber ultrafiltration experimental device was purchased from Beijing Xubang Membrane Equipment Co., Ltd.
2 方法2 Methods
2.1间接ELISA检测方法的操作步骤2.1 Operation steps of indirect ELISA detection method
(1)包被:以优化后的CF作为包被抗原,稀释到最佳浓度后加入酶标板(100μL/孔),孵育一段时间后,将酶标板内的液体弃掉,经PBST洗涤后将酶标板拍干。(1) Coating: Use the optimized CF as the coating antigen, dilute it to the optimal concentration and add it to the ELISA plate (100 μL/well). After incubation for a period of time, discard the liquid in the ELISA plate, wash it with PBST and pat the plate dry.
(2)封闭:向拍干后的酶标板中加入封闭液,200μL/孔,孵育一段时间后,将酶标板内的液体弃掉,经PBST洗涤后将酶标板拍干。(2) Blocking: Add blocking solution to the ELISA plate after tapping dry, 200 μL/well. After incubation for a period of time, discard the liquid in the ELISA plate, wash with PBST and tap the plate dry.
(3)一抗(或检测样品):将阴性血清(N)、MAP阳性血清(A)、MTB阳性血清(B)或者采集到的临床血清样品(经优化处理后)用PBST以最佳的稀释倍数稀释后加入到酶标板中,100 μL/孔,每个样本做2-3个重复,孵育一段时间后,将酶标板内的液体弃掉,经PBST洗涤后将酶标板拍干。(3) Primary antibody (or test sample): Dilute the negative serum (N), MAP positive serum (A), MTB positive serum (B) or the collected clinical serum sample (after optimization treatment) with PBST at the optimal dilution multiple and add it to the ELISA plate, 100 μL/well, and perform 2-3 replicates for each sample. After incubation for a period of time, discard the liquid in the ELISA plate, wash with PBST and pat the ELISA plate dry.
(4)酶标二抗:将最优二抗用PBST稀释后加入到酶标板中,100 μL/孔,孵育一段时间后,将酶标板内的液体弃掉,经PBST洗涤后将酶标板拍干。(4) Enzyme-labeled secondary antibody: Dilute the optimal secondary antibody with PBST and add it to the ELISA plate at 100 μL/well. After incubation for a period of time, discard the liquid in the ELISA plate, wash with PBST, and pat the plate dry.
(5)显色:每孔加入100 μL最佳显色液,显色一段时间(避光)。(5) Color development: Add 100 μL of the best color developing solution to each well and allow the color to develop for a period of time (avoid light).
(6)终止反应:向每孔中加入100 μL终止液。(6) Stop reaction: Add 100 μL of stop solution to each well.
(7)读值。(7) Reading value.
2.2间接ELISA检测过程中各条件的优化2.2 Optimization of various conditions during indirect ELISA detection
2.2.1 包被缓冲液的筛选2.2.1 Screening of coating buffer
分别用PBS(0.01 mol/L)、CBS(0.05 mol/L)和Tris-HCl(20 mmol/L)作为包被缓冲液稀释CF,初步试验中分别用这3种包被液将包被原稀释至50 μg/mL,100 μL/孔加入酶标板中,4℃孵育12h后,用PBST洗涤三次,每次间隔3min,最后一次洗涤后拍干酶标板(该步骤简称洗涤),用PBST稀释脱脂乳至5%作为封闭液,200μL/孔加入酶标板,37℃封闭2h后,重复洗涤程序,将阴性血清(N)、MAP阳性血清(A)、MTB阳性血清(B)用PBST做100倍稀释作为一抗,100μL/孔,37℃ 孵育1h后重复洗涤程序,兔抗牛二抗(HRP标记)5,000倍稀释作为二抗,37℃ 孵育1h后重复洗涤程序,以TMB(天根)作为显色液,37℃ 显色10 min后用2M 硫酸作为终止液每孔加入100μL,每孔均设两个平行对照,显色终止后读取OD450nm值。根据A/B和A/N值的大小筛选出最佳包被缓冲液。PBS (0.01 mol/L), CBS (0.05 mol/L) and Tris-HCl (20 mmol/L) were used as coating buffer to dilute CF. In the preliminary experiment, the three coating solutions were used to dilute the coating source to 50 μg/mL, 100 μL/well was added to the ELISA plate, incubated at 4°C for 12 hours, washed three times with PBST, each time with an interval of 3 minutes, and the ELISA plate was patted dry after the last wash (this step is referred to as washing). Skim milk was diluted to 5% with PBST as blocking solution, 200 μL/well was added to the ELISA plate, blocked at 37°C for 2 hours, and the washing procedure was repeated. Negative serum (N), MAP positive serum (A), and MTB positive serum (B) were diluted 100 times with PBST as primary antibodies, 100 μL/well, incubated at 37°C for 1 hour, and the washing procedure was repeated. Rabbit anti-bovine secondary antibody (HRP labeled) was diluted 5,000 times as secondary antibody and incubated at 37°C for 1 hour. After incubation for 1 hour, the washing procedure was repeated, TMB (Tiangen) was used as the color developing solution, and 2M sulfuric acid was used as the stop solution after color development at 37°C for 10 minutes, and 100 μL was added to each well. Two parallel controls were set up for each well, and the OD450nm value was read after color development was terminated. The best coating buffer was screened according to the size of A/B and A/N values.
2.2.2包被抗原浓度的初步优化2.2.2 Preliminary optimization of coating antigen concentration
用筛选出的最佳包被缓冲液将CF浓度稀释至5 μg/mL、10 μg/mL、20 μg/mL、30 μg/mL、40 μg/mL、50 μg/mL、75 μg/mL、100 μg/mL、150 μg/mL、200 μg/mL,共10个梯度,分别包被酶标板。以5%脱脂乳作为封闭液,血清做100倍稀释,兔抗牛二抗(HRP标记)5,000倍稀释作为二抗,TMB(天根)显色后,用2M的硫酸终止反应,每孔均设两个平行对照,试验完成后,读取OD450nm值。根据A/B和A/N值的大小筛选出最佳包被浓度。The optimal coating buffer was used to dilute the CF concentration to 5 μg/mL, 10 μg/mL, 20 μg/mL, 30 μg/mL, 40 μg/mL, 50 μg/mL, 75 μg/mL, 100 μg/mL, 150 μg/mL, and 200 μg/mL, a total of 10 gradients, and the ELISA plate was coated separately. 5% skim milk was used as the blocking solution, serum was diluted 100 times, rabbit anti-bovine secondary antibody (HRP labeled) was diluted 5,000 times as the secondary antibody, TMB (Tiangen) was used for color development, and 2M sulfuric acid was used to terminate the reaction. Two parallel controls were set up for each well. After the experiment was completed, the OD450nm value was read. The optimal coating concentration was screened according to the size of the A/B and A/N values.
2.2.3包被时间的优化2.2.3 Optimization of coating time
将CF稀释至最佳浓度后,试验5种条件包被酶标板,分别为37℃ 孵育1 h,37℃ 孵育2 h,4℃ 孵育过夜,37℃ 孵育1 h后4℃过夜,37℃ 孵育2 h后4℃ 过夜。以5% v/v脱脂乳作为封闭液,血清做100倍稀释,兔抗牛二抗(HRP标记)5,000倍稀释作为二抗,TMB(天根)显色后,用2M的硫酸终止反应,每孔均设两个平行对照,试验完成后,读取OD450nm值。根据A/B和A/N值的大小筛选出最佳包被时间。After CF was diluted to the optimal concentration, five conditions were tested for coating the ELISA plate, namely, incubation at 37℃ for 1 h, incubation at 37℃ for 2 h, incubation at 4℃ overnight, incubation at 37℃ for 1 h and then at 4℃ overnight, and incubation at 37℃ for 2 h and then at 4℃ overnight. 5% v/v skim milk was used as the blocking solution, serum was diluted 100 times, rabbit anti-bovine secondary antibody (HRP labeled) was diluted 5,000 times as the secondary antibody, TMB (Tiangen) was used for color development, and 2M sulfuric acid was used to terminate the reaction. Two parallel controls were set for each well. After the test was completed, the OD450nm value was read. The optimal coating time was screened according to the size of the A/B and A/N values.
2.2.4封闭液的初步筛选2.2.4 Preliminary screening of blocking solution
用最佳包被缓冲液将CF在最佳浓度稀释后,按照最佳包被时间包被酶标板后进行封闭液的优化。初步选择5% v/v脱脂乳、1% v/vPEG-2000、5% v/v明胶、5% v/v羊血清、5%v/v马血清、5% v/v猪血清、1% v/v脱脂乳+5% v/v猪血清、5% v/v兔血清、1% v/v脱脂乳+5%v/v兔血清、5% v/v鸡血清、5% v/v BCG免疫过的兔血清、5% v/v Msg免疫过的兔血清、1%v/v BSA、SurMODics-Fish、Thermo-PBS作为封闭液,37℃ 封闭2h,血清做100倍稀释,兔抗牛二抗(HRP标记)5,000倍稀释作为二抗,TMB(天根)显色后,用2M的硫酸终止反应,每孔均设两个平行对照,试验完成后,读取OD450nm值。根据A/B和A/N值的大小筛选出较优的封闭液。After diluting CF at the optimal concentration with the optimal coating buffer, the ELISA plate was coated according to the optimal coating time and the blocking solution was optimized. 5% v/v skim milk, 1% v/v PEG-2000, 5% v/v gelatin, 5% v/v sheep serum, 5% v/v horse serum, 5% v/v pig serum, 1% v/v skim milk + 5% v/v pig serum, 5% v/v rabbit serum, 1% v/v skim milk + 5% v/v rabbit serum, 5% v/v chicken serum, 5% v/v BCG-immunized rabbit serum, 5% v/v Msg-immunized rabbit serum, 1% v/v BSA, SurMODics-Fish, and Thermo-PBS were initially selected as blocking solutions. The cells were blocked at 37°C for 2 hours, the serum was diluted 100 times, and the rabbit anti-bovine secondary antibody (HRP labeled) was diluted 5,000 times as the secondary antibody. After color development with TMB (Tian Gen), the reaction was terminated with 2M sulfuric acid. Two parallel controls were set up in each well. After the experiment was completed, the OD450nm value was read. The better blocking solution was screened out according to the A/B and A/N values.
2.2.5血清抗体中非特异性因素的吸附2.2.5 Adsorption of nonspecific factors in serum antibodies
分别培养Msg、M. Phlei和BCG,将待检血清稀释后,加入等体积的三种细菌CF(参照实施例1步骤2.3.2的方法),分别4℃ 作用过夜(12 h),37℃ 作用30min,37℃ 作用2 h后加入到酶标板中,兔抗牛二抗(HRP标记)5,000倍稀释作为二抗,TMB(天根)显色后,用2 M的硫酸终止反应,每孔均设两个平行对照,试验完成后,读取OD450nm值。根据A/B和A/N值的大小筛选出较优的可以用于吸收和去除血清抗体中能够与其他分枝杆菌属发生交叉反应的CF抗原。Msg, M. Phlei and BCG were cultured separately, and the serum to be tested was diluted and then added with equal volumes of three kinds of bacterial CF (refer to the method of step 2.3.2 of Example 1), and then added to the ELISA plate after being exposed to 4°C overnight (12 h), 37°C for 30 min, and 37°C for 2 h, respectively. Rabbit anti-bovine secondary antibody (HRP labeled) was diluted 5,000 times as the secondary antibody, and TMB (Tiangen) was used for color development, and 2 M sulfuric acid was used to terminate the reaction. Two parallel controls were set up for each well. After the test was completed, the OD450nm value was read. According to the size of the A/B and A/N values, the better CF antigens that can be used to absorb and remove serum antibodies that can cross-react with other mycobacteria were screened.
2.2.6包被浓度、封闭液、封闭时间和血清稀释倍数的优化2.2.6 Optimization of coating concentration, blocking solution, blocking time and serum dilution multiple
根据之前的实验结果,选择包被浓度、封闭液、封闭时间和血清稀释倍数四个因素各三个水平做L9(34)正交试验设计。包被浓度选择初筛中最佳的三个浓度;封闭液选择初筛中最佳成分的三种不同的浓度配比;封闭时间分别选择37℃ 30min、37℃ 1 h和37℃ 2 h;血清稀释倍数选择20倍、50倍和100倍三个稀释倍数。兔抗牛二抗(HRP标记)5,000倍稀释作为二抗,TMB(天根)显色后,用2M的硫酸终止反应,每孔均设两个平行对照,试验完成后,读取OD450nm值。对实验结果进行统计学分析,以确定最佳的包被浓度、封闭液、封闭时间和血清稀释倍数。According to the previous experimental results, four factors, namely, coating concentration, blocking solution, blocking time and serum dilution multiple, were selected with three levels for L 9 (3 4 ) orthogonal experimental design. The coating concentration selected the three best concentrations in the initial screening; the blocking solution selected three different concentration ratios of the best components in the initial screening; the blocking time selected 37℃ 30min, 37℃ 1h and 37℃ 2h respectively; the serum dilution multiple selected 20 times, 50 times and 100 times. Rabbit anti-bovine secondary antibody (HRP labeled) was diluted 5,000 times as the secondary antibody. After TMB (Tiangen) color development, the reaction was terminated with 2M sulfuric acid. Two parallel controls were set for each well. After the experiment was completed, the OD450nm value was read. The experimental results were statistically analyzed to determine the optimal coating concentration, blocking solution, blocking time and serum dilution multiple.
2.2.7不同二抗的筛选及二抗稀释倍数的优化2.2.7 Screening of different secondary antibodies and optimization of secondary antibody dilution multiples
分别选择HRP标记的羊抗牛多克隆抗体(二抗1)、兔抗牛(全血清中产生)IgG抗体(二抗2)、兔抗牛(Fc特异性)IgG抗体(二抗3)、HRP标记的兔抗牛(亲和分离抗体)IgG抗体(二抗4)和HRP标记的兔抗牛(抗血清IgG部分)IgG抗体(二抗5)五种二抗,由于二抗2和二抗3没有HRP标记,所以首先进行酶标抗体的制备。Five secondary antibodies were selected, including HRP-labeled goat anti-bovine polyclonal antibody (secondary antibody 1), rabbit anti-bovine (produced in whole serum) IgG antibody (secondary antibody 2), rabbit anti-bovine (Fc-specific) IgG antibody (secondary antibody 3), HRP-labeled rabbit anti-bovine (affinity separation antibody) IgG antibody (secondary antibody 4) and HRP-labeled rabbit anti-bovine (antiserum IgG part) IgG antibody (secondary antibody 5). Since
取2.5 mg HRP溶于0.25 mL去离子水中,向其中加入高碘酸钠(0.06 mol/L)(新鲜配制)水溶液0.25 mL,4℃ 混匀30 min后向其中加入乙二醇(0.16 mol/L)水溶液0.25 mL,室温放置30 min,向其中加入含有2.5 mg纯化兔抗牛IgG的水溶液0.25 mL,混匀后加入透析卡中,将透析卡放入0.05 mol/L的CBS (pH=9.5)中4℃ 过夜透析。从透析卡中吸出液体,加入硼氢化钠溶液(5 mg/mL) 0.1 mL, 4℃ 静置2 h。向其中加入等体积的饱和硫酸铵溶液(pH=7.0),4℃ 静置30 min后,3,500 rpm/min离心30 min,弃上清,将沉淀用PBS(0.02mol/L;pH=7.4)悬起加入透析卡,将透析卡放入PBS中4℃ 透析过夜,期间换液三次后吸出透析卡中的液体,离心除去不溶物后即获得HRP标记的二抗。Dissolve 2.5 mg HRP in 0.25 mL deionized water, add 0.25 mL sodium periodate (0.06 mol/L) (freshly prepared) aqueous solution, mix at 4°C for 30 min, add 0.25 mL ethylene glycol (0.16 mol/L) aqueous solution, let stand at room temperature for 30 min, add 0.25 mL aqueous solution containing 2.5 mg purified rabbit anti-bovine IgG, mix well, add to dialysis card, put the dialysis card in 0.05 mol/L CBS (pH=9.5) at 4°C overnight for dialysis. Aspirate the liquid from the dialysis card, add 0.1 mL sodium borohydride solution (5 mg/mL), and let stand at 4°C for 2 h. An equal volume of saturated ammonium sulfate solution (pH=7.0) was added thereto, and the mixture was allowed to stand at 4°C for 30 min. The mixture was centrifuged at 3,500 rpm/min for 30 min, and the supernatant was discarded. The precipitate was suspended in PBS (0.02 mol/L; pH=7.4) and added to a dialysis card. The dialysis card was placed in PBS and dialyzed overnight at 4°C. During the period, the liquid was changed three times, and the liquid in the dialysis card was aspirated. After centrifugation to remove insoluble matter, the HRP-labeled secondary antibody was obtained.
用最佳包被缓冲液将CF在最佳浓度稀释后,按照最佳包被时间包被酶标板,加入优化后的封闭液孵育一段时间后,加入最佳稀释度的血清样本,分别将5种抗体按照1:5,000、1:10,000、1:20,000、1:50,000和1:100,000进行稀释,作用一段时间后,用TMB(天根)显色,2M的硫酸终止反应,每孔均设两个平行对照,试验完成后,读取OD450nm值。根据A/B和A/N值的大小筛选出最佳的二抗及其稀释倍数。After diluting CF at the optimal concentration with the optimal coating buffer, the ELISA plate was coated according to the optimal coating time. After adding the optimized blocking solution and incubating for a period of time, the serum sample with the optimal dilution was added, and the five antibodies were diluted at 1:5,000, 1:10,000, 1:20,000, 1:50,000 and 1:100,000 respectively. After a period of action, TMB (Tiangen) was used for color development, and 2M sulfuric acid was used to terminate the reaction. Two parallel controls were set up for each well. After the test was completed, the OD450nm value was read. The best secondary antibody and its dilution multiple were selected according to the size of the A/B and A/N values.
2.2.8血清样本及二抗作用时间的优化2.2.8 Optimization of serum samples and secondary antibody action time
用最佳包被缓冲液将CF在最佳浓度稀释后,按照最佳包被时间包被酶标板,加入优化后的封闭液孵育一段时间后,加入最佳稀释度的血清样本,分别在37℃ 孵育30 min、45 min和60 min后加入优化后的二抗,按最佳稀释倍数稀释后加入酶标板分别在37℃ 孵育30 min、45 min和60 min。TMB(天根)显色后,用2M的硫酸终止反应,每孔均设两个平行对照,其余按照间接ELISA的方法操作,试验完成后,读取OD450nm值。根据A/B和A/N值的大小筛选出最优的血清样本及二抗的作用时间。After diluting CF at the optimal concentration with the optimal coating buffer, the ELISA plate was coated according to the optimal coating time. After adding the optimized blocking solution and incubating for a period of time, the serum sample with the optimal dilution was added, and incubated at 37°C for 30 min, 45 min and 60 min, respectively. After adding the optimized secondary antibody, it was diluted according to the optimal dilution multiple and added to the ELISA plate and incubated at 37°C for 30 min, 45 min and 60 min. After TMB (Tiangen) color development, the reaction was terminated with 2M sulfuric acid. Two parallel controls were set up in each well, and the rest were operated according to the indirect ELISA method. After the test was completed, the OD450nm value was read. The optimal serum sample and the action time of the secondary antibody were screened according to the size of the A/B and A/N values.
2.2.9显色液和终止液的筛选2.2.9 Screening of colorimetric and stop solutions
用最佳包被缓冲液将CF在最佳浓度稀释后,按照最佳包被时间包被酶标板,加入优化后的封闭液孵育一段时间后,加入最佳稀释度的血清样本和二抗,显色时分别选择来自于sigma、上海生工、amresco 、thermo和天根公司的5种不同品牌的TMB显色液,终止时分别选择2M的硫酸和0. 05%的氢氟酸作为终止液,每孔均设两个平行对照,其余按照间接ELISA的方法操作,试验完成后,读取OD450nm或OD630nm值。根据A/B和A/N值的大小筛选出最优的显色液和终止液。After diluting CF at the optimal concentration with the optimal coating buffer, the ELISA plate was coated according to the optimal coating time. After adding the optimized blocking solution and incubating for a period of time, the serum sample and secondary antibody at the optimal dilution were added. When developing the color, 5 different brands of TMB color developing solutions from Sigma, Shanghai Shenggong, Amresco, Thermo and Tiangen were selected. When stopping, 2M sulfuric acid and 0.05% hydrofluoric acid were selected as stop solutions. Two parallel controls were set for each well, and the rest were operated according to the indirect ELISA method. After the test was completed, the OD450nm or OD630nm value was read. The optimal color developing solution and stop solution were selected according to the size of the A/B and A/N values.
2.2.10显色时间和显色温度的优化2.2.10 Optimization of color development time and color development temperature
用最佳包被缓冲液将CF在最佳浓度稀释后,按照最佳包被时间包被酶标板,加入优化后的封闭液孵育一段时间后,加入最佳稀释度的血清样本和二抗,加入最佳显色液后,将作用时间分别设为5 min、10 min和15 min,作用温度分别选择22℃(常温)和37℃,做双因素交叉实验。加入终止液后读取OD450nm或OD630nm值。每孔均设两个平行对照,其余按照间接ELISA的方法操作,根据A/B和A/N值的大小筛选出最佳的显色时间和显色温度。After diluting CF at the optimal concentration with the optimal coating buffer, the ELISA plate was coated according to the optimal coating time. After adding the optimized blocking solution and incubating for a period of time, the serum sample and secondary antibody at the optimal dilution were added. After adding the optimal color development solution, the action time was set to 5 min, 10 min and 15 min, and the action temperature was selected at 22°C (normal temperature) and 37°C, respectively, and a two-factor crossover experiment was performed. After adding the stop solution, the OD450nm or OD630nm value was read. Two parallel controls were set for each well, and the rest were operated according to the indirect ELISA method. The optimal color development time and color development temperature were screened according to the size of the A/B and A/N values.
2.2.11洗涤步骤的优化2.2.11 Optimization of washing steps
用最佳包被缓冲液将CF在最佳浓度稀释后,按照最佳包被时间包被酶标板,加入优化后的封闭液孵育一段时间后,加入最佳稀释度的血清样本和二抗,按照优化后的条件进行显色,终止后读取OD450nm或OD630nm值,每孔均设两个平行对照。整个操作过程中的洗涤步骤设为以下3种方式,连续洗涤3次,最后一次拍干;洗涤3次,每次间隔1 min,最后一次拍干;洗涤3次(3 min/次),最后一次拍干。其余按照间接ELISA的方法操作,根据A/B和A/N值的大小筛选出最佳的洗涤方法。After diluting CF at the optimal concentration with the optimal coating buffer, the ELISA plate was coated according to the optimal coating time. After adding the optimized blocking solution and incubating for a period of time, the serum sample and secondary antibody at the optimal dilution were added, and the color was developed according to the optimized conditions. After termination, the OD450nm or OD630nm value was read, and two parallel controls were set for each well. The washing steps in the whole operation process were set as follows: wash 3 times continuously, and pat dry the last time;
2.3阴阳性临界值的确定2.3 Determination of positive and negative critical values
按照2.2中优化的结果,检测200份细菌培养为MAP阴性的血清,读值后计算所有血清的OD的平均值()和标准差(SD),根据和SD计算临界值,当检测临床样本时,根据临床样本OD值(S或)(有重复孔的样本要计算平均值),标准阳性血清OD值(P)和标准阴性血清OD值(N),按照以下公式进行计算:According to the optimized results in 2.2, 200 sera with MAP-negative bacterial cultures were tested, and the average OD of all sera was calculated after reading the values ( ) and standard deviation (SD), and the critical value is calculated based on the OD value (S or ) (the average value should be calculated for samples with duplicate wells), the standard positive serum OD value (P) and the standard negative serum OD value (N) are calculated according to the following formula:
S/P(%)=100× S/P (%) = 100 ×
以+3×SD的值作为MAP阳性临界值,以+2×SD的值作为MAP阴性临界值,若值在两者之间,判为MAP抗体可疑,应重新检测。by The value of +3×SD was used as the positive cutoff value of MAP. The value of +2×SD is used as the MAP negative critical value. If the value is between the two, it is judged as suspicious for MAP antibodies and should be retested.
2.4建立的间接ELISA方法的效果评价2.4 Evaluation of the effect of the established indirect ELISA method
2.4.1特异性实验2.4.1 Specificity experiments
(1)交叉反应检测(1) Cross-reaction detection
选择结核分枝杆菌阳性血清(MTB)、牛传染性鼻气管炎阳性血清(IBR)、牛副流感病毒阳性血清(BPIV)、布鲁氏菌阳性血清(布病),口蹄疫阳性血清(口蹄疫),牛无乳支原体阳性血清(牛无乳),牛病毒性腹泻病阳性血清(BVDV)、牛大肠杆菌(28a)阳性血清(大肠28a),牛大肠杆菌(空载体)阳性血清(大肠空),牛支原体阳性血清(牛支)等10种牛在临床中常患疾病的阳性血清,通过优化后的ELISA方法进行检测,每种血清重复4孔,该实验重复两次,结果根据S/P(%)值进行判断,若MAP阳性血清的S/P(%)值不低于 +3×SD的值,其他10种疾病阳性血清的S/P(%)值不高于 +2×SD的值,则无交叉反应,特异性良好。Ten positive sera of cattle diseases commonly seen in clinical practice were selected, including Mycobacterium tuberculosis positive serum (MTB), bovine infectious rhinotracheitis positive serum (IBR), bovine parainfluenza virus positive serum (BPIV), Brucella positive serum (brucellosis), foot-and-mouth disease positive serum (FMD), bovine Mycoplasma agalactiae positive serum (bovine agalactiae), bovine viral diarrhea positive serum (BVDV), bovine Escherichia coli (28a) positive serum (E. coli 28a), bovine Escherichia coli (empty vector) positive serum (E. coli empty), and Mycoplasma bovis positive serum (bovine Mycoplasma). The optimized ELISA method was used for detection. Each serum was repeated in 4 wells. The experiment was repeated twice. The results were judged based on the S/P (%) value. If the S/P (%) value of the MAP positive serum was not less than +3×SD, the S/P (%) values of the positive sera of the other 10 diseases were not higher than If the value is +2×SD, there is no cross-reaction and the specificity is good.
(2)200份阴性血清检测(2) 200 negative serum samples tested
选择200份细菌培养为MAP阴性的血清,按照优化好的间接ELISA操作程序进行检测,每个血清做2个重复,阴阳性结果根据S/P(%)值进行判断,计算阳性检出率。200 sera with MAP-negative bacterial culture were selected and tested according to the optimized indirect ELISA procedure. Each serum was repeated twice, and the positive and negative results were judged according to the S/P (%) value, and the positive detection rate was calculated.
2.4.2敏感性实验2.4.2 Sensitivity test
(1)阳性质控血清检测(1) Positive quality control serum test
将MAP阳性血清用PBST按照1:100、1:200、1:500、1:1,000、1:1,500、1:3,000、1:5,000七个梯度稀释,其他步骤按照优化后的间接ELISA方法进行检测,酶标仪读值后,根据S/P(%)值计算敏感性。The MAP-positive serum was diluted with PBST according to seven gradients of 1:100, 1:200, 1:500, 1:1,000, 1:1,500, 1:3,000, and 1:5,000. The other steps were detected according to the optimized indirect ELISA method. After the microplate reader read the value, the sensitivity was calculated according to the S/P (%) value.
(2)50份阳性血清检测(2) 50 positive serum samples tested
选择50份细菌培养为MAP阳性的血清,按照优化好的间接ELISA操作程序进行检测,每个血清做2个重复,阴阳性结果根据S/P(%)值进行判断,计算阳性检出率。Fifty sera that were MAP-positive in bacterial culture were selected and tested according to the optimized indirect ELISA procedure. Each serum was repeated twice, and the positive and negative results were judged based on the S/P (%) value, and the positive detection rate was calculated.
2.4.3重复性实验2.4.3 Repeatability Experiment
(1)批内重复性实验(1) Intra-batch reproducibility test
在同一批制备的包被CF的酶标板中随机选择4块,按照优化好的方法对20份血清(包括MAP强阳性血清6份、MAP弱阳性血清8份和MAP阴性血清6份)样品进行检测。每块板子上的每份血清(重复3孔)取平均值与其他板子上的该血清的平均值进行比较,计算4块板子中每份血清总体和SD,根据公式SD/×100%计算批内变异系数(C×V%),确定批内重复性。Four ELISA plates coated with CF were randomly selected from the same batch of prepared plates, and 20 serum samples (including 6 MAP strong positive serum samples, 8 MAP weak positive serum samples and 6 MAP negative serum samples) were tested according to the optimized method. The average value of each serum sample (repeated 3 wells) on each plate was compared with the average value of the serum sample on other plates, and the total value of each serum sample in the four plates was calculated. and SD, according to the formula SD/ ×100% to calculate the intra-batch coefficient of variation (C×V%) and determine the intra-batch repeatability.
(2)批间重复性实验(2) Batch reproducibility experiment
从不同批次制备的包被CF的酶标板中随机选择3块,按照优化好的方法对上述20份血清样品进行检测。每块板子上的每份血清(重复3孔)取平均值与其他板子上的该血清的平均值进行比较,计算3块板子中每份血清总体和SD,根据公式SD/×100%计算批间变异系数(C×V%),确定批间重复性。Randomly select 3 ELISA plates coated with CF prepared in different batches, and test the above 20 serum samples according to the optimized method. Take the average value of each serum (repeated 3 wells) on each plate and compare it with the average value of the serum on other plates, and calculate the total value of each serum in the three plates. and SD, according to the formula SD/ ×100% was used to calculate the inter-batch coefficient of variation (C×V%) and determine the inter-batch repeatability.
2.4.4符合实验2.4.4 Compliance experiment
将CF包被的酶标板封闭后,连同13份MAP阳性血清和19份MAP阴性血清、二抗、TMB显色液、终止液、洗液和稀释液组装成试剂盒,选择具有代表性的上海、新疆和合肥三个地区进行符合实验,每个地区由不同的人进行实验操作,阴阳性结果根据S/P(%)值进行判断,计算阳性符合率。After the CF-coated ELISA plate was blocked, it was assembled into a kit together with 13 MAP-positive sera and 19 MAP-negative sera, secondary antibody, TMB colorimetric solution, stop solution, washing solution and diluent. Three representative regions, namely Shanghai, Xinjiang and Hefei, were selected for the coincidence experiment. The experimental operations were performed by different people in each region. The positive and negative results were judged according to the S/P (%) value, and the positive coincidence rate was calculated.
2.4.5对比试验2.4.5 Comparative test
选择细菌培养后已知阴阳性的MAP血清250份,分别用组装后的检测试剂盒与IDEXX的副结核分枝杆菌抗体检测试剂盒进行检测,将实验结果汇总后进行比较。250 MAP sera with known positive and negative results after bacterial culture were selected and tested using the assembled detection kit and IDEXX's Mycobacterium paratuberculosis antibody detection kit respectively. The experimental results were summarized and compared.
2.4.6保存期实验2.4.6 Shelf life experiment
将组装后的试剂盒抽取6盒,在2~8℃ 保存12个月,分别于1、2、3、6、9、12个月时抽取一盒进行各部分相关实验,并与新组装的试剂盒进行比较,首先检测各溶液体积、外观颜色是否变化,是否产生沉淀物,酶标板是否封闭良好,选择2.3.3中的20份血清,对酶标板进行符合率、特异性和敏感性实验,根据实验结果判定试剂盒稳定性。Take out 6 boxes of the assembled test kit and store them at 2-8℃ for 12 months. Take out one box at 1, 2, 3, 6, 9 and 12 months for related experiments of each part and compare them with the newly assembled test kit. First, check whether the volume and appearance color of each solution have changed, whether precipitate has been produced, and whether the ELISA plate is well blocked. Select the 20 sera in 2.3.3, and conduct compliance, specificity and sensitivity experiments on the ELISA plate. Determine the stability of the test kit based on the experimental results.
2.4.7临床血清样本的检测2.4.7 Testing of clinical serum samples
选取来自于乌鲁木齐的牛血清585份、双鸭山的牛血清1015份、长春的牛血清123份、上海的牛血清58份、浙江的牛血清10份、河南的牛血清44份、合肥的牛血清65份共1900份临床血清样本进行ELISA检测(采集或由当地送检)。这1900份血清来自于不同的省市,遍及东北、西北、华东及中原地区,能够在一定程度上代表我国MAP的流行情况。A total of 1900 clinical serum samples were selected for ELISA testing (collected or sent locally), including 585 bovine sera from Urumqi, 1015 bovine sera from Shuangyashan, 123 bovine sera from Changchun, 58 bovine sera from Shanghai, 10 bovine sera from Zhejiang, 44 bovine sera from Henan, and 65 bovine sera from Hefei. These 1900 sera came from different provinces and cities, covering the Northeast, Northwest, East China and Central Plains, and can represent the prevalence of MAP in my country to a certain extent.
3 结果3 Results
3.1间接ELISA检测过程中各条件的优化3.1 Optimization of various conditions during indirect ELISA detection
3.1.1包被缓冲液的筛选3.1.1 Screening of coating buffer
分别用PBS(0.01 mol/L)、CBS(0.05 mol/L)和Tris-HCl(20 mmol/L)作为包被缓冲液稀释CF至50 μg/mL,按照间接ELISA的操作步骤完成实验,酶标仪读值后对A/B及A/N的值进行分析,结果表明(见表8),当包被缓冲液为Tris-HCl(20 mmol/L)时,A/B和A/N的值最佳。所以后续试验选择Tris-HCl(20 mmol/L)作为包被缓冲液。PBS (0.01 mol/L), CBS (0.05 mol/L) and Tris-HCl (20 mmol/L) were used as coating buffers to dilute CF to 50 μg/mL. The experiment was completed according to the operating steps of indirect ELISA. The values of A/B and A/N were analyzed after the microplate reader read the values. The results showed (see Table 8) that when the coating buffer was Tris-HCl (20 mmol/L), the values of A/B and A/N were the best. Therefore, Tris-HCl (20 mmol/L) was selected as the coating buffer in subsequent experiments.
3.1.2抗原包被浓度的初步优化3.1.2 Preliminary optimization of antigen coating concentration
将CF用筛选出的最佳包被缓冲液稀释至5 μg/mL-200 μg/mL范围内的10个浓度梯度,分别包被酶标板后进行间接ELISA检测,酶标仪读值后对A/B及A/N的值进行分析,结果表明(见图6),当包被浓度为30 μg/mL、40 μg/mL和50 μg/mL 时,A/B和A/N值均较高。因此,初步选择这三个浓度进行后续实验。CF was diluted to 10 concentration gradients in the range of 5 μg/mL-200 μg/mL with the selected optimal coating buffer, and then coated on the ELISA plate for indirect ELISA detection. The A/B and A/N values were analyzed after the ELISA instrument read the values. The results showed (see Figure 6) that when the coating concentration was 30 μg/mL, 40 μg/mL and 50 μg/mL, the A/B and A/N values were high. Therefore, these three concentrations were initially selected for subsequent experiments.
3.1.3包被时间的优化3.1.3 Optimization of coating time
将CF包被时间分被设为37℃孵育1 h,37℃孵育2 h,4℃ 孵育过夜(12 h),37℃孵育1h后4℃ 过夜,37℃孵育2 h后4℃ 过夜。按照间接ELISA操作步骤检测,酶标仪读值后对A/B及A/N的值进行分析,结果表明(见表9),当包被时间为4℃ 孵育过夜时,A/B和A/N值均较高。所以,选择包被抗原4℃ 孵育过夜为最佳包被时间。The CF coating time was set to 1 h at 37℃, 2 h at 37℃, 12 h at 4℃ overnight, 1 h at 37℃ and then 4℃ overnight, and 2 h at 37℃ and then 4℃ overnight. According to the indirect ELISA operation steps, the A/B and A/N values were analyzed after the microplate reader read the values. The results showed (see Table 9) that when the coating time was 4℃ overnight, the A/B and A/N values were higher. Therefore, the best coating time was to choose the coating antigen and incubate at 4℃ overnight.
3.1.4封闭液的初步筛选3.1.4 Preliminary screening of blocking solution
初步选择5%脱脂乳和1% PEG-2000等15种材料作为封闭液,37℃ 封闭2 h后,按照间接ELISA操作步骤检测,酶标仪读值后对A/B及A/N的值进行分析,结果表明(见图7),当封闭液为1% v/v脱脂乳+5% v/v猪血清时,A/B和A/N值均较高,因此,初步选择脱脂乳添加猪血清作为封闭液的成分进行后续优化。Fifteen materials including 5% skim milk and 1% PEG-2000 were initially selected as blocking solutions. After blocking at 37°C for 2 h, the samples were tested according to the indirect ELISA procedure. The A/B and A/N values were analyzed after reading the values with an enzyme reader. The results showed (see Figure 7) that when the blocking solution was 1% v/v skim milk + 5% v/v porcine serum, both the A/B and A/N values were higher. Therefore, skim milk plus porcine serum was initially selected as the component of the blocking solution for subsequent optimization.
3.1.5血清抗体中非特异性因素的吸附3.1.5 Adsorption of nonspecific factors in serum antibodies
分别选取Msg、M. Phlei和BCG三种细菌的CF作为吸收和去除血清抗体中能够与其他分枝杆菌属发生交叉反应的抗原,与稀释后的血清等体积混合后,分别在4℃ 过夜(12h),37℃ 30 min,37℃ 2h这三种条件下进行相互作用,之后按照间接ELISA的操作步骤进行检测,酶标仪读值后对A/B及A/N的值进行分析,结果显示(见表10),综合考虑A/B和A/N的值,M. Phlei的CF对血清抗体中的非特异性因素的吸收与去除效果较好,但是相互作用的时间和温度对结果产生的影响并不大,考虑到实际实验操作过程中应尽可能的节省时间,所以选择M.Phlei的CF与稀释后的血清抗体进行作用,作用时间为37℃ 30 min。CF of three bacteria, Msg, M. Phlei and BCG, were selected as antigens that can cross-react with other mycobacteria in serum antibodies and were mixed with equal volumes of diluted serum. The mixture was allowed to interact at 4°C overnight (12h), 37°C for 30 min, and 37°C for 2h, respectively. The test was then carried out according to the operating procedures of indirect ELISA. The A/B and A/N values were analyzed after the microplate reader read the values. The results showed (Table 10) that, considering the A/B and A/N values, the CF of M. Phlei had a better effect on absorbing and removing nonspecific factors in serum antibodies. However, the interaction time and temperature had little effect on the results. Considering that time should be saved as much as possible in the actual experimental operation, the CF of M. Phlei was selected to react with the diluted serum antibodies at 37°C for 30 min.
3.1.6包被浓度、封闭液、封闭时间和血清稀释倍数的优化3.1.6 Optimization of coating concentration, blocking solution, blocking time and serum dilution multiple
根据之前的实验结果,选择包被浓度、封闭液、封闭时间和血清稀释倍数四个因素各三个水平做L9(34)正交试验设计(如表11所示)。抗原包被浓度选择30 μg/mL、40 μg/mL和50 μg/mL;封闭液选择1% v/v脱脂乳+1% v/v猪血清(封闭液1)、1%脱脂乳+3%猪血清(封闭液2)和1% v/v脱脂乳+5% v/v猪血清(封闭液3);封闭时间分别选择37℃ 30 min、37℃ 1h和37℃ 2 h;血清稀释倍数选择20倍、50倍和100倍三个稀释倍数,每孔均设两个平行对照。之后按照间接ELISA的操作步骤进行检测,实验完成后,读取OD450nm值。对实验结果进行统计学分析,如表12,方差分析结果显示,包被浓度和血清稀释倍数对A/N值的影响极显著(α=0.01)包被浓度、封闭液和血清稀释倍数对A/N值的影响显著(α=0.05)。封闭时间对结果的影响不显著。由图8可以看出,差异主要来源于包被浓度中的30 μg/mL和40μg/mL、封闭液中的1和3同时还有血清稀释倍数中的20倍和100倍稀释。因此,可以确定,最佳的包被浓度为50 μg/mL,封闭液选择1% v/v脱脂乳+3% v/v猪血清,封闭时间选择37℃ 1h,血清稀释倍数选择50倍稀释。According to the previous experimental results, four factors, namely, coating concentration, blocking solution, blocking time and serum dilution multiple, were selected with three levels for L 9 (3 4 ) orthogonal experimental design (as shown in Table 11). The antigen coating concentration was selected as 30 μg/mL, 40 μg/mL and 50 μg/mL; the blocking solution was selected as 1% v/v skim milk + 1% v/v pig serum (blocking solution 1), 1% skim milk + 3% pig serum (blocking solution 2) and 1% v/v skim milk + 5% v/v pig serum (blocking solution 3); the blocking time was selected as 37℃ 30 min, 37℃ 1h and 37℃ 2 h respectively; the serum dilution multiple was selected as 20 times, 50 times and 100 times, and two parallel controls were set for each well. Then, the detection was carried out according to the operating steps of indirect ELISA, and the OD 450nm value was read after the experiment was completed. The experimental results were statistically analyzed, as shown in Table 12. The results of variance analysis showed that the coating concentration and serum dilution multiple had extremely significant effects on the A/N value (α=0.01). The coating concentration, blocking solution and serum dilution multiple had significant effects on the A/N value (α=0.05). The blocking time had no significant effect on the results. As can be seen from Figure 8, the differences mainly came from 30 μg/mL and 40 μg/mL in the coating concentration, 1 and 3 in the blocking solution, and 20-fold and 100-fold dilutions in the serum dilution multiple. Therefore, it can be determined that the optimal coating concentration is 50 μg/mL, the blocking solution is 1% v/v skim milk + 3% v/v pig serum, the blocking time is 37℃ 1h, and the serum dilution multiple is 50-fold dilution.
3.1.7不同二抗的筛选及二抗稀释倍数的优化3.1.7 Screening of different secondary antibodies and optimization of secondary antibody dilution multiples
将五种抗体分别做5,000,10,000,20,000,50,000,100,000倍稀释,按照间接ELISA的检测方法检测,酶标仪读值后对A/B及A/N的值进行分析,结果表明(见图9、图10),当二抗为二抗2时即HRP标记后的兔抗牛(Fc特异性)IgG抗体时,A/B和A/N的值都明显优于其他二抗,同时在HRP标记后的兔抗牛(Fc特异性)IgG抗体作为二抗时,当稀释倍数为10,000时,A/B和A/N的值最佳。因此,选择HRP标记后的兔抗牛(Fc特异性)IgG抗体作为二抗,稀释倍数为10,000。The five antibodies were diluted 5,000, 10,000, 20,000, 50,000, and 100,000 times, respectively, and tested according to the indirect ELISA detection method. The A/B and A/N values were analyzed after the enzyme marker read the values. The results showed (see Figure 9 and Figure 10) that when the secondary antibody was
3.1.8血清样本及二抗作用时间的优化3.1.8 Optimization of serum samples and secondary antibody action time
将血清样本和二抗的作用时间分别设为37℃孵育30 min、45 min和60 min进行双因素交叉试验,按照间接ELISA的操作方法完成试验后,酶标仪OD450nm读值,对A/B及A/N的值进行分析,如图11所示,在血清样本作用45min,二抗作用45 min时,A/N的值明显优于其他时间的组合,同时,A/B的值也较高,综合考虑A/B及A/N的值,同时考虑到在实验的操作过程中要尽可能的节省时间,所以最终选择血清样本和二抗均孵育45 min作为最佳的孵育时间。The action time of serum samples and secondary antibodies was set to 37°C for 30 min, 45 min and 60 min, respectively, for a two-factor crossover test. After completing the test according to the indirect ELISA operation method, the OD450nm value of the microplate reader was read, and the A/B and A/N values were analyzed. As shown in Figure 11, when the serum sample was incubated for 45 min and the secondary antibody was incubated for 45 min, the A/N value was significantly better than the other time combinations. At the same time, the A/B value was also higher. Considering the A/B and A/N values comprehensively and taking into account the need to save as much time as possible during the experimental operation, the serum sample and the secondary antibody were incubated for 45 min as the optimal incubation time.
3.1.9显色液和终止液的筛选3.1.9 Screening of colorimetric and stop solutions
分别选择来自于5个不同公司生产的TMB 作为显色液,选择2 M的硫酸和0.05%的氢氟酸作为终止液,每孔均设两个平行对照,其余按照间接ELISA的方法操作,酶标仪读值后对A/B及A/N的值进行分析,结果表明(见图12),使用amresco的TMB显色在用0.05%的氢氟酸进行终止时,OD630nm读值,A/B及A/N的值要明显优于其他组合。TMB produced by 5 different companies was selected as the colorimetric solution, 2 M sulfuric acid and 0.05% hydrofluoric acid were selected as the stop solution, two parallel controls were set up in each well, and the rest were operated according to the indirect ELISA method. The A/B and A/N values were analyzed after the microplate reader read the values. The results showed (see Figure 12) that when using amresco's TMB colorimetric solution and 0.05% hydrofluoric acid for termination, the OD630nm readings, A/B and A/N values were significantly better than other combinations.
3.1.10显色时间和显色温度的优化3.1.10 Optimization of color development time and color development temperature
选择显色时间5 min、10 min和15 min,显色温度22℃(常温)和37℃做双因素交叉实验,每孔均设两个平行对照,其余按照间接ELISA的方法操作,酶标仪读值后对A/B及A/N的值进行分析,结果表明(见表13),当显色时间为10 min时,A/B及A/N的值要明显高于其他时间,37℃的A/B及A/N的值要明显优于22℃,虽然在显色15分钟时,A值较高,但同时B值和N值也相对较高,所以综合考虑,选择37℃显色10 min作为最佳显色条件。A two-factor crossover experiment was performed with color development times of 5 min, 10 min and 15 min and color development temperatures of 22°C (normal temperature) and 37°C. Two parallel controls were set up in each well, and the rest were operated according to the indirect ELISA method. The A/B and A/N values were analyzed after the microplate reader read the values. The results showed (see Table 13) that when the color development time was 10 min, the A/B and A/N values were significantly higher than those at other times, and the A/B and A/N values at 37°C were significantly better than those at 22°C. Although the A value was higher when the color development time was 15 minutes, the B value and N value were also relatively high at the same time. Therefore, considering all factors, 37°C for 10 min was selected as the optimal color development condition.
3.1.11洗涤步骤的优化3.1.11 Optimization of washing steps
将ELISA操作过程中的洗涤步骤设为以下3种方式,连续洗涤3次,最后一次拍干;洗涤3次(1 min/次),最后一次拍干;洗涤3次(3 min/次),最后一次拍干。其余按照间接ELISA的方法操作,读取A/B和A/N值后发现,各组间均无明显差别,考虑到时间成本及操作的方便性,选择连续洗涤3次,最后一次拍干作为洗涤方法。The washing steps in the ELISA operation process were set to the following three methods: continuous washing for 3 times, patting dry at the last time; washing 3 times (1 min/time), patting dry at the last time; washing 3 times (3 min/time), patting dry at the last time. The rest was operated according to the indirect ELISA method. After reading the A/B and A/N values, it was found that there was no significant difference between the groups. Considering the time cost and convenience of operation, continuous washing for 3 times and patting dry at the last time was selected as the washing method.
3.2阴阳性临界值的确定3.2 Determination of positive and negative critical values
按照2.2中优化的结果,检测200份细菌培养为MAP阴性的血清,OD630nm读值后计算所有血清的OD平均值及标准差,根据平均值和标准差作图(见图13),如图所示,可以分析出,数据的分布趋向于正态分布,该组数据的平均值()为0.286,标准差(SD)为0.0695。以+3×SD的值为MAP阳性临界值,即0.5,以+2×SD的值为MAP阴性临界值,即0.425。因此,当临床样本检测完成后,根据临床样本OD630nm读值(S或)(有重复孔的样本要计算平均值),标准阳性血清OD630nm值(P)和标准阴性血清OD630nm值(N),按照以下公式进行计算:According to the optimized results in 2.2, 200 sera with MAP-negative bacterial cultures were tested. The OD630nm readings were used to calculate the OD mean and standard deviation of all sera. A graph was drawn based on the mean and standard deviation (see Figure 13). As shown in the figure, it can be analyzed that the distribution of the data tends to be normal distribution. The mean value of this group of data ( ) is 0.286, and the standard deviation (SD) is 0.0695. The value of +3×SD is the positive critical value of MAP, which is 0.5. The value of +2×SD is the MAP negative critical value, which is 0.425. Therefore, after the clinical sample test is completed, according to the clinical sample OD630nm reading (S or ) (the average value should be calculated for samples with duplicate wells), the standard positive serum OD630nm value (P) and the standard negative serum OD630nm value (N) are calculated according to the following formula:
S/P(%)=100× S/P (%) = 100 ×
当S/P值大于等于50%时,该临床样本判定为MAP阳性,当S/P值小于等于42.5%时,该临床样本判定为MAP阴性,当S/P值大于42.5%且小于50%时,则该临床样本判定为可疑,应复检。When the S/P value is greater than or equal to 50%, the clinical sample is judged to be MAP positive; when the S/P value is less than or equal to 42.5%, the clinical sample is judged to be MAP negative; when the S/P value is greater than 42.5% and less than 50%, the clinical sample is judged to be suspicious and should be retested.
3.3间接ELISA方法的效果评价3.3 Evaluation of the effect of indirect ELISA method
3.3.1特异性实验3.3.1 Specificity experiment
(1)交叉反应检测(1) Cross-reaction detection
选择10种牛在临床中常患疾病的阳性血清,通过优化后的ELISA方法进行检测,酶标仪读值后对S/P(%)值进行分析,结果表明(见图14),MAP阳性血清的S/P(%)值大于50%,其他10种疾病阳性血清的S/P(%)值小于42.5%,证明该检测方法特异性良好。Positive sera for 10 common diseases in cattle were selected and tested using the optimized ELISA method. The S/P (%) values were analyzed after reading with an enzyme labeler. The results showed (see Figure 14) that the S/P (%) value of MAP-positive sera was greater than 50%, and the S/P (%) values of the positive sera for the other 10 diseases were less than 42.5%, demonstrating that the detection method has good specificity.
(2)200份阴性血清检测(2) 200 negative serum samples tested
选择200份细菌培养为MAP阴性的血清,按照优化好的间接ELISA操作程序进行检测,每个血清做2个重复,计算检测结果的S/P值,200份血清中有9份血清S/P(%)值大于50%,为阳性血清,其余血清的S/P(%)值均小于42.5%。因此,本方法特异性为95.5%(9/200)。200 sera with negative MAP in bacterial culture were selected and tested according to the optimized indirect ELISA operation procedure. Two replicates were performed for each serum and the S/P value of the test results was calculated. Among the 200 sera, 9 sera had S/P (%) values greater than 50%, which were positive sera, and the S/P (%) values of the remaining sera were all less than 42.5%. Therefore, the specificity of this method was 95.5% (9/200).
3.3.2敏感性实验3.3.2 Sensitivity test
(1)阳性质控血清检测(1) Positive quality control serum test
将MAP阳性血清用PBST稀释七个梯度,其他步骤按照优化后的间接ELISA方法进行检测,酶标仪读值后,计算S/P(%)值,结果显示(见表14),当阳性血清稀释到1,000倍时,S/P(%)值仍大于50%,为阳性,证明本实验的检测方法具有高度敏感性。The MAP-positive serum was diluted seven times with PBST, and the other steps were detected according to the optimized indirect ELISA method. After the microplate reader read the value, the S/P (%) value was calculated. The results showed (see Table 14) that when the positive serum was diluted to 1,000 times, the S/P (%) value was still greater than 50%, which was positive, proving that the detection method of this experiment has high sensitivity.
(2)50份阳性血清检测(2) 50 positive serum samples tested
选择50份细菌培养为MAP阳性的血清,按照优化好的间接ELISA操作程序进行检测,每个血清做2个重复,计算检测结果的S/P值,100份血清中有46份血清S/P(%)值大于50%,为阳性血清,其余血清的S/P(%)值均小于42.5%。因此,本方法敏感性为92.0%(46/50)。50 sera with MAP positive bacterial culture were selected and tested according to the optimized indirect ELISA operation procedure. Each serum was repeated twice and the S/P value of the test results was calculated. Among the 100 sera, 46 sera had S/P (%) values greater than 50%, which were positive sera, and the S/P (%) values of the remaining sera were all less than 42.5%. Therefore, the sensitivity of this method was 92.0% (46/50).
3.3.3重复性实验3.3.3 Repeatability experiment
(1)批内重复性实验(1) Intra-batch reproducibility test
计算4块板子中每份血清总体和SD,根据公式SD/×100%计算出批内变异系数(C×V%)如表15所示,C×V%在1.04%~9.97%之间,均小于10%,说明本方法批内重复性良好。Calculate the total serum volume of each serum sample in the 4 plates and SD, according to the formula SD/ The intra-batch coefficient of variation (C×V%) was calculated by 100% as shown in Table 15. The C×V% was between 1.04% and 9.97%, all less than 10%, indicating that this method had good intra-batch repeatability.
(2)批间重复性实验(2) Batch reproducibility experiment
计算3块板子中每份血清总体和SD,根据公式SD/ ×100%计算批间变异系数(C×V%),如表16,C×V%在3.16%~9.44%之间,均小于10%,说明本方法批间重复性良好。Calculate the total serum volume of each serum sample in the three plates. and SD, according to the formula SD/ ×100% was used to calculate the inter-batch coefficient of variation (C×V%). As shown in Table 16, C×V% was between 3.16% and 9.44%, all less than 10%, indicating that this method had good inter-batch repeatability.
3.3.4符合实验3.3.4 Compliance experiment
上海、新疆和合肥三个地区的符合实验检出结果均为13份MAP阳性血清,19份MAP阴性血清。说明本实验重复性良好。The results of the three regions of Shanghai, Xinjiang and Hefei were consistent with the results of the experiment, with 13 MAP-positive sera and 19 MAP-negative sera, indicating that the experiment had good repeatability.
3.3.5对比试验3.3.5 Comparative test
分别用本方法组装的试剂盒和IDEXX的副结核分枝杆菌抗体检测试剂盒检测 250份血清,计算符合率,结果如表17。因此本方法组装的试剂盒与IDEXX的副结核分枝杆菌抗体检测试剂盒符合率(%)=(47+189)/250×100%=94.4%。250 serum samples were tested with the kit assembled by this method and the Mycobacterium paratuberculosis antibody detection kit of IDEXX, and the compliance rate was calculated. The results are shown in Table 17. Therefore, the compliance rate (%) of the kit assembled by this method and the Mycobacterium paratuberculosis antibody detection kit of IDEXX = (47 + 189) / 250 × 100% = 94.4%.
3.3.6保存期试验3.3.6 Shelf life test
将组装后的试剂盒抽取6盒,在2~8℃保存12个月,分别于1、2、3、6、9、12个月时抽取一盒进行各部分相关实验,并与新组装的试剂盒进行比较,首先检测各溶液体积,所有试剂剂量和外观颜色无明显变化,并未产生沉淀物,酶标板封闭良好。对酶标板进行符合率实验,20血清阴阳性完全相符,与上文中10种其他疾病的阳性血清均无交叉反应,特异性敏感性与新组装的试剂盒完全一致,表明试剂盒稳定性良好,可以稳定保存12个月。Six boxes of the assembled kit were extracted and stored at 2-8°C for 12 months. One box was extracted at 1, 2, 3, 6, 9, and 12 months for related experiments in each part, and compared with the newly assembled kit. First, the volume of each solution was tested. There was no obvious change in the dosage and appearance color of all reagents, no precipitation was produced, and the ELISA plate was well sealed. The ELISA plate was tested for the coincidence rate, and the positive and negative of the 20 sera were completely consistent, and there was no cross reaction with the positive sera of the 10 other diseases mentioned above. The specific sensitivity was completely consistent with the newly assembled kit, indicating that the kit has good stability and can be stably stored for 12 months.
3,4临床血清样本的检测3,4 Detection of clinical serum samples
取来自于不同省市1900份临床血清样本,这些血清样本遍及东北、西北、华东及中原地区,能够在一定程度上代表我国MAP的流行情况。检测结果表明在1900份血清中,有MAP阳性血清96份,阳性率为5.05%。1,900 clinical serum samples were collected from different provinces and cities. These serum samples were distributed throughout the Northeast, Northwest, East China and Central Plains, and can represent the prevalence of MAP in my country to a certain extent. The test results showed that among the 1,900 serum samples, 96 were MAP-positive, with a positive rate of 5.05%.
3.5试剂盒的初步组装3.5 Initial Assembly of the Kit
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310215284.5A CN115902217B (en) | 2023-03-08 | 2023-03-08 | Indirect ELISA (enzyme-Linked immuno sorbent assay) detection kit for bovine paratuberculosis and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310215284.5A CN115902217B (en) | 2023-03-08 | 2023-03-08 | Indirect ELISA (enzyme-Linked immuno sorbent assay) detection kit for bovine paratuberculosis and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115902217A CN115902217A (en) | 2023-04-04 |
CN115902217B true CN115902217B (en) | 2023-06-16 |
Family
ID=86496431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310215284.5A Active CN115902217B (en) | 2023-03-08 | 2023-03-08 | Indirect ELISA (enzyme-Linked immuno sorbent assay) detection kit for bovine paratuberculosis and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115902217B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN119901564A (en) * | 2025-04-02 | 2025-04-29 | 天津海关动植物与食品检测中心 | A sample diluent and its application in a bovine paratuberculosis screening kit and product |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090052175A (en) * | 2007-11-20 | 2009-05-25 | 대한민국(관리부서 : 농림수산식품부 국립수의과학검역원) | Right tuberculosis specific enzyme immunoassay kit using immunospecific protein antigen and right tuberculosis diagnostic method using same |
WO2021209339A1 (en) * | 2020-04-13 | 2021-10-21 | Neiker, Instituto Vasco De Investigación Y Desarrollo Agrario, S.A. | In vitro method for diagnosing subjects infected with mycobacterium species |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19621488C2 (en) * | 1996-05-29 | 1998-05-14 | Gerlach Gerald F Prof Dr | Diagnostic procedure for the detection of subclinical mammals suffering from paratuberculosis |
US20030157589A1 (en) * | 1998-12-11 | 2003-08-21 | Mary Jackson | Method of screening anti-mycobacterial molecules |
GB0019721D0 (en) * | 2000-08-10 | 2000-09-27 | Regma Biotechnologies Ltd | Novel method |
JP3675778B2 (en) * | 2002-04-09 | 2005-07-27 | 日本ビーシージー製造株式会社 | Active tuberculosis / active mycobacteriosis determination reagent, test plate to which this reagent is adhered, and active tuberculosis / active mycobacteria determination method using these |
WO2008030865A1 (en) * | 2006-09-08 | 2008-03-13 | Wisconsin Alumni Research Foundation | Assay for antibodies to mycobacterium paratuberculosis |
CA2698826A1 (en) * | 2006-11-06 | 2008-05-15 | Baptiste Leroy | New antigens for paratuberculosis diagnosis and vaccination |
EP2052737A1 (en) * | 2007-10-26 | 2009-04-29 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Synthetic antigenic peptides and lipopeptides derived from mycobacterium avium subsp. paratuberculosis |
EP2265955A1 (en) * | 2008-03-18 | 2010-12-29 | Wisconsin Alumni Research Foundation | Mycobacterial culture screening test for mycobacterium avium complex bacteria |
DE102008029833A1 (en) * | 2008-06-25 | 2010-01-21 | Justus-Liebig-Universität Giessen | Method for early detection of infection with MAP |
DE102008029834A1 (en) * | 2008-06-25 | 2010-01-14 | Justus-Liebig-Universität Giessen | Method for the specific detection of MAP antibodies |
RU2410425C1 (en) * | 2009-09-23 | 2011-01-27 | Государственное научное учреждение Всероссийский научно-исследовательский институт пантового оленеводства Сибирского отделения Россельхозакадемии (ГНУ ВНИИПО СО Россельхозакадемии) | Culture medium for growing mycobacterium tuberculosis |
CN101949928A (en) * | 2010-08-26 | 2011-01-19 | 江苏出入境检验检疫局动植物与食品检测中心 | Kit for detecting alpaca mycobacterium paratuberculosis antibody and detection method thereof |
UA60423U (en) * | 2010-09-14 | 2011-06-25 | Национальный Научный Центр "Институт Экспериментальной И Клинической Ветеринарной Медицины" | Nutrient medium for cultivation of m.paratuberculosis |
US9663758B2 (en) * | 2013-03-12 | 2017-05-30 | Wisconsin Alumni Research Foundation | Global gene regulators (GGR) as vaccine candidates against paratuberculosis |
CN105181963B (en) * | 2015-07-30 | 2017-08-01 | 西北农林科技大学 | Preparation method of ELISA detection kit for goat pseudotuberculosis antibody |
HUE051349T2 (en) * | 2016-03-22 | 2021-03-01 | Glaxosmithkline Ip Dev Ltd | Antituberculosis agent |
CN105907770B (en) * | 2016-05-16 | 2019-07-05 | 河北农业大学 | Recombinant gene, recombinant protein encoded by it, application thereof, and detection kit and detection method of Paramycobacterium bovis |
GB201913705D0 (en) * | 2019-09-23 | 2019-11-06 | Univ Belfast | Detection of mycobacterium species |
-
2023
- 2023-03-08 CN CN202310215284.5A patent/CN115902217B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090052175A (en) * | 2007-11-20 | 2009-05-25 | 대한민국(관리부서 : 농림수산식품부 국립수의과학검역원) | Right tuberculosis specific enzyme immunoassay kit using immunospecific protein antigen and right tuberculosis diagnostic method using same |
WO2021209339A1 (en) * | 2020-04-13 | 2021-10-21 | Neiker, Instituto Vasco De Investigación Y Desarrollo Agrario, S.A. | In vitro method for diagnosing subjects infected with mycobacterium species |
Also Published As
Publication number | Publication date |
---|---|
CN115902217A (en) | 2023-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104007269B (en) | A detection kit for Riemerella anatipestifer indirect hemagglutination antibody and its application | |
CN103278635B (en) | Animal brucellosis competitive ELISA (enzyme linked immunosorbent assay) antibody detection kit | |
US10428139B2 (en) | GM hybridoma cell, monoclonal antibody, kit and preparation method and use thereof | |
CN117447601B (en) | Antibodies to porcine IgM, antibody compositions and uses thereof | |
CN117447602B (en) | Antibodies to porcine IgM and uses thereof | |
CN115902217B (en) | Indirect ELISA (enzyme-Linked immuno sorbent assay) detection kit for bovine paratuberculosis and application thereof | |
US8158371B2 (en) | Assay for antibodies to Mycobacterium paratuberculosis | |
CN110967480A (en) | Preparation and application of pig epidemic diarrhea virus IgA antibody ELISA kit | |
Taylor et al. | Magnetic immuno capture PCR assay (MIPA): detection of Leptospira borgpetersenii serovar hardjo | |
CN105866436B (en) | A kind of Hua Nashi staphylococcuses indirect hemagglutination detection kit and its application | |
CN105646703B (en) | Cryptococcus neoformans capsular polysaccharide GXM polyclonal antibody and preparation method thereof | |
Chaya et al. | Evaluation of a newly designed sandwich enzyme linked immunosorbent assay for the detection of hydatid antigen in serum, urine and cyst fluid for diagnosis of cystic echinococcosis | |
Cho et al. | Diagnostic specificity, sensitivity and cross-reactivity of an enzyme-linked immunosorbent assay for the detection of antibody against Leptospira interrogans serovars pomona, sejroe and hardjo in cattle | |
CN116773809A (en) | A method for detecting Utiligo spores based on magnetic immuno-chemiluminescence | |
Bach et al. | Immunogenicity of PtpA secreted during Mycobacterium avium ssp. paratuberculosis infection in cattle | |
CN102435732A (en) | Toxoplasma IgM antibody immunoblotting kit and preparation method thereof | |
Gaia Collaboration et al. | A&A, this volume | |
CN102288768A (en) | Toxoplasma gondii IgG (immunoglobulin G) antibody immunoblotting kit and preparation method thereof | |
CN101349694A (en) | Streptomycin medicament fast detecting reagent kit and uses thereof | |
RU2625031C1 (en) | Immunoenzymometric test system for animals anaerobic enterotoxemia serum diagnostics and postvaccinal immunity stress control | |
Rouhollah et al. | Development and optimization a high sensitive and specific ELISA system for rapid detection of paratuberculosis in cattle | |
CN202256346U (en) | Toxoplasma IgM antibody immunoblotting kit | |
CN102323420A (en) | The total antibody mediated immunity trace of arc worm kit and preparation method thereof | |
Kalleshamurthy et al. | ccep | |
Sun et al. | Development of IMBs-qPCR method for detection of foodborne Salmonella |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |